



ODÜ TIP DERGİSİ

ODU MEDICAL JOURNAL

December 2022 Volume 9 Issue 3 e-ISSN 2148-6816



ODU TIP DERGİSİ
ODU MEDICAL JOURNAL
(ODU MED J)

OWNER

On Behalf of Ordu University

NİYAZİ TAŞCI

EDITOR

ULKU KARAMAN,

Ordu University

ASSOCIATED EDITORS

AHMET KAYA, Ordu University

AHMET KARATAŞ, Ondokuz Mayıs University

ALİ YILMAZ, Ordu University

SAİME ŞAHİNÖZ, Ordu University

NECATİ OZPINAR, Mustafa Kemal University

TUBA GÜL, Ordu University

FIELD EDITOR

Basic Medical Sciences

Ali Aslan, Ordu University, Ordu/Turkey
Gonca Gülbay, Ordu University, Ordu/Turkey
Orhan Baş, Ordu University, Ordu/Turkey
Pınar Naile Gürgör, Samsun University, Samsun/Turkey
Ülkü Karaman, Ordu University, Ordu/Turkey

Surgical Medical Sciences

Abdullah Alper Şahin, Ordu University, Ordu/Turkey
Ali Beytur, Inonu University, Malatya/Turkey
Alper Çıraklı, Ordu University, Ordu/Turkey
Deha Denizhan Keskin, Ordu University, Ordu/Turkey
Seda Keskin, Ordu University, Ordu/Turkey
Kunesko Nart, Maternity Hospital Moskova/Russian

İnternal Medical Sciences

Atakan Savrun, Ordu University, Ordu/Turkey
Emine Yurdakul, Ordu University, Ordu/Turkey
Ömer Karaman, Ordu University, Ordu/Turkey
Özgür Enginyurt, Ordu University, Ordu/Turkey
Saime Şahinöz, Ordu University, Ordu/Turkey
Serpil Şener, Inonu University, Malatya/Turkey
Sevgi Çıraklı, Ordu University, Ordu/Turkey
Yasemin Kaya, Ordu University, Ordu/Turkey

INTERNATIONAL EDITORIAL BOARD MEMBERS

Cheers Emiliano, Milan University, Italy
Fabio Esposito, Milan University, Italy
Judit Plutzer, National Institute of Environmental Health,
Hungary
Kuneshko Nart, Karolinska Institutet, Sweden

Kosta Y. Mumcuoğlu, Hebrew University of Jerusalem, Israel
Katalin Sandor, Maternity Hospital Moskova/Russian

SCIENTIFIC COMMITTEE

- Ahmet Çalışkan**, Pamukkale University, Denizli/Turkey
Ahmet Karataş, Ondokuz Mayıs University, Samsun/Turkey
Ahmet Kaya, Ordu University, Ordu/Turkey
Ali Özer, Inonu University, Malatya/Turkey
Ali Yılmaz, Ordu University, Ordu/Turkey
Aslı Aykaç, Yakın Doğu University, Kıbrıs
Arzu Şahin, Uşak University, Uşak/Turkey
Ayşegül Çebi, Giresun University, Giresun/Turkey
Ayşegül Özkan, TOBB ETÜ, Ankara/Turkey
Atakan Savrun, Etlik Hospital, Ankara/Turkey
Cemil Çolak, Inonu University, Malatya/Turkey
Durmuş Oğuz Karakoyun, Ordu University, Ordu/Turkey
Ebru Çanakçı, Ordu University, Ordu/Turkey
Emine Şamdancı, Inonu University, Malatya/Turkey
Esra Erdoğan, Gulhane Medical Faculty, Ankara/Turkey
Erdal Benli, Ordu University, Ordu/Turkey
Fatif Şal, Ordu University, Ordu/Turkey
Funda Doğruman-Al, Gazi University, Ankara/Turkey
Hakan Korkmaz, Ordu University, Ordu/Turkey
Hamza Çınar, Abant İzzet Baysal University, Bolu/Turkey
Havva Erdem, Ordu University, Ordu/Turkey
Hilal Altaş, Ordu University, Ordu/Turkey
İsmail Erkan Aydın, Ordu University, Ordu/Turkey
Kaptanıderya Tayfur, Ordu University, Ordu/Turkey
Keziban Doğan, Sadi Konuk, education Res. Hos İstanbul/Turkey
Muhammed Özbilen, Ordu University, Ordu/Turkey
Mustafa Kerem Çalgın, Ordu University, Ordu/Turkey
Necdet Özçay, Yakın Doğu University, Kıbrıs
Nilay Taş, Ordu University, Ordu/Turkey
Ömer Karaman, Ordu University, Ordu/Turkey
Özlem Özdemir, Ordu University, Ordu/Turkey
Semih Kunak, Private Clinic, Ankara/Turkey
Serpil Değerli, Cumhuriyet University, Sivas/Turkey
Sevda Önder, Private Clinic, Ordu/Turkey
Şahin Direkel, Giresun University, Giresun/Turkey
Tevfik Noyan, Ordu University, Ordu/Turkey
Tuba Gül, Ordu University, Ordu/Turkey
Tuba Şeyda Savrun, Etlik Hospital, Ankara/Turkey
Tuğba Raika Kıran, Turgut Özal University, Malatya//Turkey
Tülin Bayrak, Ordu University, Ordu/Turkey
Ülkü Karaman, Ordu University, Ordu/Turkey
Yeliz Kasko Arıcı, Ordu University, Ordu/Turkey
Yunus Güzel, INOVA hospital, Nevşehir/Turkey
Zeki Yüksel Günaydın, Giresun University, Giresun/Turkey
Zeynep Taş Cengiz, Yüzüncü Yıl University, Van/Turkey

Layout Editors

Atakan Savrun, Ordu University, Ordu
Pınar Naile Gürgör, Samsun University, Samsun, Turkey
Ülkü Karaman, Ordu University, Ordu, Turkey

Proofreading

Atakan Savrun, Ordu University, Ordu
Gonca Gülbay, Ordu University, Ordu, Turkey
Pınar Naile Gürgör, Samsun University, Samsun, Turkey
Ülkü Karaman, Ordu University, Ordu, Turkey

Secretarial Staff

Ülkü Karaman, Ordu University, Ordu/Turkey

Language Inspectors

Çağrı Akalın, Ordu University, Ordu/Turkey
Muhammed Özbilen, Ordu University, Ordu/Turkey
Sevda Önder, Private Clinic, Ordu/Turkey

Biostatistical Consultant

Adem Doğaner, Sütçü İmam University, Kahramanmaraş
Cemil Çolak, Inonu University, Malatya/Turkey
Yeliz Kasko Arıcı, Ordu University, Ordu/Turkey

Graphic Designer

Ülkü Karaman, Ordu University, Ordu/Turkey

ODU Medical Journal is published by Faculty of Medicine of Ordu University on behalf of Ordu University and provides DOI free of charge.

The content of all topics can be accessed as full text free of charge at <https://dergipark.org.tr/tr/pub/odutip/archive>.

e-ISSN 2148-6816

ODU Tıp Dergisi/ ODU Medical Journal

Editorial office:

Ordu University, Faculty of Medicine

Republic Campus

52200, Ordu, TURKEY

Telephone: +90 452 234 50 10

Fax: +90 452 226 52 55

Email: ukaraman@odu.edu.tr

ulkukaraman44@hotmail.com

Web site: <https://dergipark.org.tr/tr/pub/odutip>

Publication Date and Place: 31/12/ 2022, ORDU, TURKEY

Publication Type: Online

Index:

Open Access Policy

ODU Medical journal implements an open access policy in line with the rules of the Budapest Open Access Initiative (BOAI).

According to BOAI rules, open access is defined as “the full text of these articles being available for any user to read, download, copy, distribute, print, search or link to and browse through”.

All studies published in the ODU Medical Journal can be accessed by all internet users as of the publication date. No fee is charged from those who download the studies published in the journal.

Aim and Scope

Aim: ODU Medical Journal is an international journal and publishes clinical and scientific original research. ODU Medical Journal, published by Ordu University, publishes research articles, case reports and reviews that include fundamental innovations in health education.

The aim of the journal is to contribute to the international literature with clinical and experimental research articles, case reports and reviews in the field of health sciences.

The target audience of the journal is all scientists working in the field of health and graduate students and researchers in this field.

Scope: ODU Medical Journal is an open access and independent international journal based on impartial double-blind peer-review principles. The publication languages of the journal are English. The journal is published every four months in April, August and December and a volume is completed in three issues.

ODU Medical Journal adheres to the standards in publication ethics in research in health science and also adopts the ethical publishing principles published by Scientific Research and Publication Ethics Directive of the Council of Higher Education, Committee on Publication Ethics (COPE), Directory of Open Access Journals (DOAJ), Open Access Scholarly Publishers Association (OASPA) and the World Association of Medical Editors (WAME).

The authors are not charged for the evaluation and publication of the article.

Publication Ethics Statement

ODU Medical Journal adheres to the standards in publication ethics in research in health science and also adopts the ethical publishing principles published by Scientific Research and Publication Ethics Directive of the Council of Higher Education, Committee on Publication Ethics (COPE), Directory of Open Access Journals (DOAJ), Open Access Scholarly Publishers Association (OASPA) and the World Association of Medical Editors (WAME). The address for the principles

expressed under the title of Principles of Transparency and Best Practice in Scholarly Publishing is given below.

<https://publicationethics.org/resources/guidelines-new/principles-transparency-and-best-practice-scholarly-publishing>

Submitted studies must be original, unpublished, and not in the evaluation process of another journal. Each article is double-blindly evaluated by one of the editors and at least two referees. Plagiarism, duplication, false authorship/denied authorship, research/data fabrication, article slicing, publishing by slicing, copyright infringement and concealment of conflict of interest are considered unethical behaviors.

All articles that do not comply with ethical standards are removed from the publication even if accepted. This also applies to articles with possible irregularities and inconsistencies detected after publication.

Research Ethics

- Compliance of the articles with ethical rules is the responsibility of the authors.
- The ethical standards of the Declaration of Helsinki must be complied with in studies on humans.
- Consideration should be given to ethical principles in the design, review and conduct of research.
- The research team and participants should be fully informed about the purpose of the research, the rules of participation and the risks, if any.
- Confidentiality of the information and answers given by the research participants should be ensured. Research should be designed in such a way as to preserve the autonomy and prestige of its participants.
- Those who will participate in the research should take part in the research voluntarily and should not be under any coercion.
- The research should be planned in a way that does not put the participants at risk.
- Research should be clear and unambiguous about its independence. If there is a conflict of interest, it should be stated.
- In experimental studies, written informed consent must be obtained from participants who decide to participate in the research. The consents of the legal guardians of children, ones under guardianship and those with a confirmed mental illness must be obtained.
- If the study will be carried out in an institution or organization, the necessary approval must be obtained from this institution or organization.

- In studies with human, it should be stated in the “methods” section that “informed consent” was obtained from the participants and ethics committee approval was obtained from the institution where the study was conducted.

Authors Responsibility

Compliance of the articles with scientific and ethical rules is the responsibility of the authors. The author must provide assurance that the article is original, has not been previously published elsewhere, and is not under consideration for publication elsewhere and in another language. Applicable copyright laws and agreements must be observed. Copyrighted material (for example, tables, figures, or large quotations) should be used with appropriate permission and acknowledgements. The work of other authors, contributors, or references should be used appropriately and cited in references.

All authors must have a direct academic and scientific contribution to the submitted manuscript. So, “author” is someone who contributes to the conceptualization and design of a published research, the obtaining, analysis or interpretation of data, writing the article or critically reviewing it in terms of content. Other conditions for being an author are planning or executing and/or revising the work on the manuscript.

Funding, data collection, or overall supervision of the research group alone does not confer authorship. All individuals listed as authors must meet all the criteria listed, and any individual who meets the above criteria may be listed as an author. The order of the authors’ names should be a joint decision. All authors must indicate the author rank on the Copyright Agreement Form signed. All individuals who did not meet the criteria for authorship but contributed to the study should be listed in the "acknowledgments" section. Examples of these are people who only provide technical support, help with writing, just provide general support, and financial and material support.

All authors must declare financial relationships, conflicts of interest, and competition of interest that have the potential to affect the results of the research or scientific evaluation. If an author detects a significant error or inaccuracy in his or her published article, it is the responsibility to immediately contact and cooperate with the editor for correction or retraction of these inaccuracies.

Editor and Reviewer Responsibilities

The editor-in-chief evaluates articles regardless of the authors' ethnicity, gender, sexual orientation, nationality, religious beliefs, and political philosophy. S/he ensures that the articles submitted for publication undergo a fair double-blind peer-review. S/he guarantees that all information regarding the submitted articles will remain confidential until the article is published. The editor-in-chief is

responsible for the content and the overall quality of the publication. If necessary, it should publish an error page or make corrections.

The editor-in-chief does not allow any conflict of interest between authors, editors and referees. It has full authority to appoint a referee and is responsible for making the final decision on the articles to be published in the journal.

Reviewers should not have conflicts of interest with the research, the authors and/or the financial supporters of the research. They should reach an impartial judgment as a result of their assessment. They should ensure that all information regarding the submitted manuscripts is kept confidential and should report any copyright infringement and plagiarism on the part of the author to the editor. The referee should notify the editor of this situation and state that s/he cannot be a referee in cases where the subject of the article is not his area of expertise or s/he cannot return on time.

Reviewers and editorial board members cannot discuss articles with other people. Attention should be taken to keep the identity of the referees confidential. In some cases, with the decision of the editor, the comments of the relevant referees for the manuscript can be sent to other referees who comment on the same manuscript.

PUBLICATION POLICY

The authors undertake that their publications are created in accordance with all universal ethical rules, and research is accepted accordingly.

Authors are responsible for all statements in their work. Submitted studies should be prepared in accordance with the writing rules of the journal. Studies that do not comply with the spelling rules are rejected or sent back to the authors for correction.

The journal reserves the right to make language corrections in accepted studies without changing the content and meaning.

The journal accepts the research provided that it has not been published in another journal or publication.

All authors must state their affiliation with persons or organizations that may have a conflict of interest. If there is support received for the study, it should be stated in detail. Conflicts of interest should also be stated on the title page.

In the management and publication processes of the journal, the publication principles of the "International Committee of Medical Journal Editors (ICMJE)" and "Committee on Publication Ethics (COPE)" are taken into consideration.

Evaluation process

-Only manuscripts uploaded to the journal's system are evaluated. Studies sent via e-mail will not be evaluated.

-All submitted works go through pre-evaluation, language editing, statistics editing and referee evaluation processes. The evaluation process is carried out by the editor of the journal.

Preliminary Evaluation Process

After the manuscript is uploaded to the journal, the pre-evaluation process begins. At this stage, the editor examines the manuscript in terms of content, form, suitability for the aim and scope of the journal. As a result of this review, the editor

- may decide that the study is not suitable for the journal and reject the study.
- may resend the work to the responsible author for corrections.
- may send it to the language editor and can request correction.
- may evaluate by sending it to the statistical consultant. After this evaluation, the editor may request corrections from the author.
- may refer the article to the referees and initiates the referee evaluation process.

Peer Review Process

All articles in the journal are subject to **double-blind peer** review. To ensure the objective evaluation process, each article is evaluated by at least two independent referees who are experts in their fields. In cases where there is no consensus among the referees, the article is evaluated by the third referee. In the decision-making processes of all articles, the editor-in-chief makes the final decision.

Revizyon

Authors should mark the changes they made in the main text in color when submitting the article revision files. The responses to the referees should be specified in a separate Word file. Revised articles should be sent to the journal within one month following the decision. If the revised version of the article is not uploaded within the specified time, the revision option may be canceled. If authors need additional time for revision, they should submit their publication requests to the journal before the end of one month.

The manuscripts accepted for publication are checked again for grammar, punctuation and format. Accepted manuscripts are arranged in accordance with the publication format of the journal, and the final version is sent to the responsible author in pdf format before publication and approval is received for publication. Authors should review their article and give approval for publication. If

any correction is required in the article other than the publication format, the correction request is notified to the editor at ulkukaraman44@hotmail.com. Correction requests are evaluated by the editor and reported to the responsible author. Articles that are not approved by the corresponding author will not be published.

Plagiarism

The similarity rate control of the articles should be made on iThenticate and should be at most 20%, excluding the "References" section.

The journal is published online only.

The journal is free of charge and no publication fee is requested from the researchers.

The journal is published by Ordu University.

Journal contact

ulkukaraman44@hotmail.com

General Rules

ODU Medical Journal is an open access and independent international journal based on impartial double-blind peer-review principles. The publication languages of the journal are English and Turkish. The journal is published every four months in July, November and March and a volume is completed in three issues. ODU Medical Journal adheres to the standards in publication ethics in research in health science and also adopts the ethical publishing principles published by Scientific Research and Publication Ethics Directive of the Council of Higher Education, Committee on Publication Ethics (COPE), Directory of Open Access Journals (DOAJ), Open Access Scholarly Publishers Association (OASPA) and the World Association of Medical Editors (WAME). The authors are not charged for the evaluation and publication of the article.

SUBMISSION POLICIES

Submission of a paper to ODU Medical Journal indicates that it deals with previously unpublished original material and is not intended for publication elsewhere. Articles submitted under multiple authorship are reviewed with the assumption that all listed authors agree with the submission and a copy of the final manuscript has been approved by all authors. Once a manuscript has been accepted, it should not be published elsewhere in the same form or in another language without the written consent of the editors and publisher. If citations from other copyrighted works are included, the author(s) must obtain written permission from the copyright holders and cite the references(s) in the article. The layout and style of the article must strictly follow the instructions. No revisions or updates will be included once the manuscript has been accepted and submitted to the publisher (unless approved by the editors).

SUBMISSION GUIDELINES

The articles sent online at <https://dergipark.org.tr/tr/pub/odutip> are reviewed in ODU Medical Journal. Manuscripts submitted online are quickly assigned to referees. Authors can view the status of their articles as they progress through the review process via individual author centers on this website. Editing notification of each article will be sent to the relevant author by e-mail on the day of decision. You can create your account for online submission by going to <https://dergipark.org.tr/tr/login>. If this is your first time for submission and you don't have an existing account, you'll need to create a new one. If you are unsure whether you have an account or have forgotten your password, enter your email address in the password assistance section on the login page. If you do not have an account, click the create account link in the upper right corner of the login page. Then, you will be able to submit and monitor the progress of your articles. After

logging in, you will be presented with a link to the main menu and your author center. You can submit your manuscript from the author center. At the end of a successful submission, you will receive an e-mail confirming that the article has reached the journal. If this does not happen, please send an email to ulkukaraman44@hotmail.com. To submit your manuscript online, please prepare the text and images according to the instructions listed below. At the end of each step, you can enter and exit the manuscript submission process. However, after you submit the manuscript, you cannot edit it. Web submission is required and the instructions are available at <https://dergipark.org.tr/tr/pub/odutip/writing-rules>.

COPYRIGHT TRANSFER AGREEMENT

A signed COPYRIGHT PUBLICATION FORM must be sent by all authors during manuscript submission.

ODU Medical Journal

Editorial Office

Faculty of Medicine, Ordu University

Cumhuriyet Campus

52200, Ordu, TURKEY

Phone: +90 (452) 226 52 14-5234

Fax: +90 (452) 226 52 28

E-mail: ulkukaraman44@hotmail.com

Authors should write their information exactly (Full address, telephone and fax numbers, e-mail address and ORCID number).

PREPARATION OF THE ARTICLE

The corresponding author should submit the manuscript as described below:

• Files you need to add:

1. Title page
2. Full text
3. Tables
4. Figures/Graphics
5. Copyright Form
6. Similarity report (Similarity should be at most 20%.)
7. Cover letter
8. Ethics committee approval/consent in case reports

- When parasites, bacteria, viruses and fungi are mentioned in the main text and references, genus and species names should be written in italics and genus names should be written in capital letters.
- Abbreviations should be expanded when first mentioned and used consistently thereafter.
- Graphic files: Each figure should be a separate file.
- All figure files must be presented in sufficiently high resolution.

It is the responsibility of the authors to create the appropriate files for the electronically submitted manuscripts as stated above. The editorial office cannot convert beyond the supported file types.

ORGANIZATION OF THE MANUSCRIPT

Manuscripts should be prepared electronically using "Time News Roman" font, formatted according to A4 page size, mono-spaced throughout, with 2.5 cm margins on all sides and 12 point font. Words should not be hyphenated to fit on one line. Pages should be numbered.

A. Title page: The title page should be separate and prepared as follows.

The title page should be in Turkish and English, and the full and short title should be written. If it has been presented in congress and symposium, it should be stated.

The names of the author(s), their affiliations and ORCID numbers should be stated.

Example: Ülkü Karaman¹, Yeliz Kaşko Arıcı², Cemil Çolak³

1-First author's institution, mail, ORCID no.

2-Second author's institution, e-mail, ORCID no.

3-Third author's institution, e-mail, ORCID no.

Corresponding author's name, address, telephone (including mobile phone number) and fax numbers and e-mail address.

Ethics Committee Approval: Ethics committee approval for this study was obtained from University Clinical Research Ethics Committee (Ethical committee date and no:.....)

Author Contributions: Concept -; Design; Audit; Data Collection and/or Processing -; Analysis and/or Interpretation -; Source Search..... ..; Spelling..... ..; Critical Review

Acknowledgement:

Conflict of interest:

Financial support:

B. What should be in the main text

1. Abstract, 2. Keywords, 3. Introduction, 4. Methods, 5. Results, 6. Discussion, 7. Conclusion, 8. References, 9. Tables and Figures.

1. Abstract: The first page should include Turkish and English abstracts and keywords. Abstracts of Original Articles should be structured with subtitles (Objective, methods, results and conclusion) (200-400 words on average).

2. Keywords: Enter at least 3-6 keywords and avoid general and plural terms and multiple concepts. These keywords will be used for indexing purposes. Key words should be written under Turkish and English abstracts. Turkish keywords should be written from <http://www.bilimterimleri.com> and English keywords should be written from <https://www.nlm.nih.gov/mesh/meshhome.html>.

3. Introduction: General information about the research, and the rationale and objectives of the research should be clearly stated in this section.

4. Methods: This section should contain all the details necessary to reproduce the experiments. When using experimental animals, the methods section should clearly state that adequate precautions have been taken to minimize pain or discomfort.

5. Results: These section should present the results and interpret them clearly and concisely. Results should generally be presented descriptively and supported by figures.

6. Discussion: It should be discussed with the findings obtained using the published literature.

7. Conclusion: In this section, the conclusions obtained from the manuscript and recommendations should be written.

8. Literature references:

While citing the references, attention should be paid to cite studies originating from Turkey and the national journals (www.atifdizini.com).

References should be listed in the text in order of occurrence and should be indicated "in parentheses" where relevant.

References should be written according to the "Vancouver" system of the American National Library of Medicine (US National Library of Medicine; <http://www.nlm.nih.gov/>).

Examples: Hypotension is one of the most common and critical problems in hemodialysis patients (1, 2).

References

When citing publications, the latest and most up-to-date publications should be preferred.

All references cited in the text should be listed at the end of the article in alphabetical order by the first author followed by the year of publication.

If reference is made to a prepress publication, DOI number must be given.

The accuracy of the sources is the responsibility of the author. References should include only print or press articles.

Unpublished data, submitted articles or personal communications should be cited in the text only.

Personal interviews must be documented with a letter of consent.

All items in the list of references should be cited in the text and conversely, all references in the text should be presented in the list.

Journal title abbreviations should conform to the abbreviations adopted by the Series Title Abbreviations List, CIEPS / ISDS, Paris, 1985 (ISBN 2-904938-02-8).

Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus / MEDLINE / PubMed.

For citations with one to six authors, the names of all authors should be written. For articles with more than six authors, “et al.” should be written after six names are written. The surnames of the authors should be written in full and the initials of their names should be capitalized without any punctuation marks.

Reference examples:

Journal: Stephane A. Management of Congenital Cholesteatoma with Otoendoscopic Surgery: Case Report. *J Med Sci* 2010;30(2):803-7.

Levine WC, Pope V, Bhoomkar A, Tambe P, Lewis JS, Zaidi AA, et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. *J Infect Dis.* 1998;177(1):167–174.

Chapter of an edited book: Hornbeck P. Assay for antibody production. In: Colign JE, Kruisbeek AM, Marguiles DH, editors. *Current Protocols in Immunology*. New York: Greene Publishing Associates; 1991. p. 105-32.

A single-authored book: Fleiss JL. *Statistical Methods for Rates and Proportions*. Second Edition. New York: John Wiley and Sons; 1981. p. 105-32.

An editorial book: Balows A, Mousier WJ, Herramaflfl KL, editors. *Manual of Clinical Microbiology*. Fifth Edition. Washington DC: IRL Press. 1990. p. 105-32.

Paper: Entrala E, Mascaro C. New structural findings in *Cryptosporidium parvum* oocysts. Eighth International Congress of Parasitology (ICOPA VIII); October 10-14; Izmir-Turkey: 1994. p. 1250-75

Thesis: Erakinci G. Searching for antibodies against parasites in donors. Izmir: Ege University Health Sciences Institute. 1997.

Electronic format: Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* (serial online) 1995 Jan-Mar (cited 1996 June 5): 1(1): (24 screens). Available from: URL: <http://www.cdc.gov/ncidod/EID/cid.htm>.

FIGURES AND TABLES

Figures:

Figures should be numbered with Arabic numerals according to the order of occurrence in the text; for example: Figure 1, Figure 2, etc. Note and explanation should be written where the graphic or figure should be in the manuscript and it should be sent as a separate file in JPG format. If figures (or other small parts) of articles or books already published elsewhere are used in the articles submitted to the ODU Medical Journal, the written permission of the relevant authors and the relevant publisher should be attached to the article. In these cases, the original source should be mentioned in the figure description. The article should not contain any information that may indicate a person or institution. All submitted figures must have a clear resolution and large size (minimum dimensions: 100 × 100 mm) to avoid delays in the evaluation process.

Tables: Tables should be created with titles and explanations. Tables should appear in the main document, follow the references, and be numbered in the order in which they are cited in the main text. Each of the numeric data tables should be typed (single-spaced) and numbered sequentially with Arabic numerals (Tables 1, 2, etc.); for example: Table 1, Table 2, etc. in the text. The title of each table should appear above it. A detailed description of its contents and footnotes should be given below the body of the table. **Corrections:** Authors should mark the changes they made in the main text in color when submitting the article revision files. The responses to the referees should be specified in a separate Word file. Revised articles should be sent to the journal within one month following the decision. If the revised version of the article is not uploaded within the specified time, the revision option may be canceled. If authors need additional time for revision, they should submit their publication requests to the journal before the end of one month.

FINAL STATEMENT OF THE ARTICLE BEFORE PUBLICATION AND OTHER NOTES TO CONSIDER

Final version of the manuscript before publication The final version of the manuscript will be sent as pdf by e-mail before publication. Only the printer's errors can be corrected. At this stage, no changes or additions will be allowed to the edited manuscripts. It should be noted that editing is solely the responsibility of the authors. A form with questions from the copy editor can be attached to the proofs. Please answer all questions and make any necessary corrections or additions.

Corrections in reviews must be returned by email within 48 hours of receipt. If the publisher does not receive any response from the authors after 3 days, it will be assumed that there are no errors to be corrected and the manuscript will be published.

Page rates

The journal is free and does not charge any publication fee from the authors.

The journal is published online only.

The similarity rate control of the articles should be made on iThenticate and should be at most 20%, excluding the "References" section.

The editorial board has the authority to make the necessary revisions (without making any changes in the context) in the manuscript format that does not comply with the above-mentioned conditions.

TYPES OF ARTICLES

Studies submitted to the journal are accepted as Original research, Short paper and Case report,

a) Research articles: Prospective, retrospective and all kinds of experimental studies

Structure

Title

Abstract should be structured (Objective, Methods, Results, and Conclusion) (200-400 words)

Keywords

Introduction

Methods

Results

Discussion

Conclusion

Acknowledgement

References (up to 40)

Except for the references and the English abstract, the full text should not exceed 4500 words.

b) Case Report: These are articles that differ in diagnosis and treatment, which are rarely seen.

They should be supported by adequate photographs and diagrams.

Structure

Title

Abstract (average 100-300 words)

Keywords

Introduction

Case report

Discussion

Conclusion

Acknowledgement

References (up to 20)

Except for the references and the English abstract, the full text should not exceed 2200 words.

c) Review

Structure

Title

Abstract (average 200-400 words)

Keywords

Introduction

The review also includes subtitles suitable for the text.

Conclusion

Acknowledgement

References (up to 50)

Except for the references and the English abstract, the full text should not exceed 6550 words.

CONTENTS

<i>Editorial</i>	Number of pages
Ulku Karaman.....	XX
Original Articles	
1. İpek Balıkçı Çiçek, Zeynep Küçükakçalı Application with Multilayer Perceptron and Radial Basis Function from Neural Network-Based Methods to Predict Cervical Cancer.....	83-93
2. Türkan Mutlu Yar, Tülay Aksoy, İpek Balıkçı Çiçek, Metin Atambay. A retrospective evaluation of the prevalence of anti- Echinococcus granulosus in patients with suspected cystic echinococcosis at İnönü University Faculty of Medicine Turgut Özal Medical Center between 2018 and 2022.....	94-103
3. Burak Yağın Detection of Coronary Heart Disease by Data Mining Methods Using Clinical Data.....	104-109
Case Report	
4. Havva Erdem, Ülkü Karaman Hydatid Cyst Mimickers and Cases Mimicked by Hydatid Cyst; With Two Cases.....	110-115
5. Gülden Yıldız, Hatice Beşeren Havadar, Tülay Diken Allahverdi Barrett's Esophagus; Case Report.....	116-121

As 2022 Ends

In these days when we leave another year behind, we are extremely happy to present the last issue of our magazine for 2022 to our valued readers with its rich content written with different perspectives, interesting topics, and current approaches.

With each passing year, while enriching our experiences with what they provide, it once again reveals that there are still many mysteries that have not been discovered scientifically. With a new year, we can sail to new horizons in our journey in the sea of science, giving us the chance to shed light on the undiscovered secrets of science.

I would like to express my sincere gratitude to all our authors who have shared their scientific and academic studies with us for publication in our journal so far and who will share them in the future, and to our valuable referees who have contributed to increasing our publication quality with their evaluations, and to all my colleagues for their efforts with devotion until our journal reaches the publication stage.

I hope that 2023 that will leave a mark on the scientific track, and bring goodness and well-being to the whole world.

Happy new year to everyone, hope to meet you in brand new issues and wish you a good read.....

PhD, Assoc. Prof. Ülkü KARAMAN

Editor

ARAŞTIRMA MAKALLES/ RESEARCH ARTICLE

Application with Multilayer Perceptron and Radial Basis Function from Neural Network-Based Methods to Predict Cervical Cancer

İpek Balıkçı Çiçek¹(ID), Zeynep Küçükakçalı¹(ID)

¹Department of Biostatistics and Medical Informatics, Faculty of Medicine, Inonu University, Malatya, Turkey.

Received: 22 September 2022, Accepted: 17 November 2022, Published online: 31 December 2022
© Ordu University Institute of Health Sciences, Turkey, 2022

Abstract

Objective: Cervical cancer is the fourth most prevalent malignancy among women worldwide. Low- and middle-income countries are much more burdened than high-income nations. Therefore, the need to develop new diagnostic techniques to predict the course of the disease and the prognosis of this malignancy has increased. In this study, cervical cancer will be classified to create an accurate diagnostic predictive model using the machine learning method The Multilayer Perceptron (MLPNN) and Radial Based ANN (RBFNN), and disease-related risk factors will be determined.

Methods: This current study considered the open-access data set of patients that cervical cancer and no-cervical cancer samples. For this purpose, data from 72 patients were included. The data set was divided as 80:20 as a training and test dataset. MLPNN and RBFNN were used for the classification Accuracy, specificity, AUC, positive predictive value, and negative predictive value performance metrics were evaluated for model performance.

Results: Among the performance criteria in the test stage obtained from the RBFNN model that has the best classification result; accuracy, specificity, AUC, positive predictive value, and negative predictive value were obtained as 92.3%, 100.0%, 96.5%, 100.0%, and 91.6%, respectively. According to the variable importance obtained as a result of the model, the variables most associated with the diagnosis were behavior sexual risk, empowerment abilities, and motivation strength, respectively.

Conclusion: The applied machine learning model successfully classified cervical cancer and created a highly accurate diagnostic prediction model. With the parameters determined as a result of the modeling, the clinician will be able to simplify and facilitate the decision-making process for the diagnosis of cervical cancer.

Key Words: Cervical cancer, classification, machine learning, Multilayer Perceptron, Radial Based ANN.

Sinir Ağı Tabanlı Yöntemlerden Çok Katmanlı Algılayıcı ve Radyal Bazlı Sinir Ağı ile Rahim Ağzı Kanseri Tahmin Etmek için Uygulam

Özet

Amaç: Rahim ağzı kanseri dünya çapında kadınlar arasında en sık görülen dördüncü malignitedir. Düşük ve orta gelirli ülkeler, yüksek gelirli ülkelerden çok daha fazla yük altındadır. Bu nedenle, hastalığın seyrini ve bu malignitenin prognozunu tahmin etmek için yeni teşhis tekniklerinin geliştirilmesi ihtiyacı artmıştır. Bu çalışmada Çok Katmanlı Algılayıcı (MLPNN) ve Radyal Tabanlı Yapay Sinir Ağları (RBFNN) makine öğrenimi yöntemleri kullanılarak rahim ağzı kanserini sınıflandıran bir tahmin modeli oluşturmak ve hastalıkla ilişkili risk faktörleri belirlemektir.

Metod: Bu çalışmada, rahim ağzı kanseri olan ve rahim ağzı kanseri olmayan hastaları içeren açık erişim veri seti dikkate alınmıştır. Bu veri setinde toplam 72 hasta bulunmaktadır. Veri seti eğitim ve test veri seti olarak 80:20 olarak bölünmüştür. Sınıflandırma için MLPNN ve RBFNN kullanılmıştır. Modelin performansı doğruluk, seçicilik, AUC, pozitif tahmin değeri ve negatif tahmin değeri performans metrikleri ile değerlendirildi.

Bulgular: En iyi sınıflandırma sonucuna sahip olan RBFNN modelinden elde edilen test aşamasındaki performans kriterlerinden; doğruluk, seçicilik, AUC, pozitif tahmin değeri ve negatif tahmin değeri sırasıyla %92.3, %100.0, %96.5, %100.0 ve %91.6 olarak elde edilmiştir. Model sonucunda elde edilen değişken önemliliklerine göre tanı ile en çok ilişkili değişkenler sırasıyla riskli cinsel davranış, güçlendirme yetenekleri ve motivasyon gücüdür.

Sonuç: Uygulanan makine öğrenimi modeli, rahim ağzı kanserini başarılı bir şekilde sınıflandırmıştır ve yüksek doğrulukta bir tanısal tahmin modeli oluşturulmuştur. Modelleme sonucunda belirlenen değişkenler ile klinisyenlerin rahim ağzı kanseri tanısına karar verme süreci basitleştirebilecek ve kolaylaştırabilecektir.

Anahtar Kelimeler: Rahim ağzı kanseri, sınıflandırma, makine öğrenimi, Çok Katmanlı Algılayıcı, Radyal Tabanlı Yapay Sinir Ağları.

Suggested Citation: Balıkçı Çiçek I, Küçükakçalı Z. Application with Multilayer Perceptron and Radial Basis Function from Neural Network-Based Methods to Predict Cervical Cancer. ODU Med J, 2022;9(3): 83-93

Copyright@Author(s) - Available online at <https://dergipark.org.tr/tr/pub/odutip>

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Address for correspondence/reprints:

İpek Balıkçı Çiçek

Telephone number: +90 422 341 0660/1337

E-mail: ipek.balikci@inonu.edu.tr

INTRODUCTION

Cervical cancer is one of the most common cancers in women. It is the third rank in the world, and it is reported that approximately 569 thousand women are diagnosed with cervical cancer every year and 311,000 women die due to cervical cancer (1). Human papilloma virus (HPV) is considered to be the primary cause of cervical cancer worldwide. Cervical cancer is one of the preventable types of cancer, and comprehensive planning based on vaccination against HPV and regular HPV-based screening has been shown to be cost-effective in almost all countries. However, due to the difficulty of accessing the vaccine in underdeveloped countries and the inadequacy of cervical cancer screening, the measures are not to the desired extent (2).

The way to reduce the number of deaths from cervical cancer is early detection. Especially in countries where screening programs are not available, early detection of this type of cancer and initiation of effective treatment significantly

increases the probability of survival. Under current circumstances, this disease is often not diagnosed until it has progressed, or treatment is available. This causes a high mortality rate in cervical cancer. By understanding and detecting the symptoms of cervical cancer, patients can be diagnosed early (3).

Researchers working in the field of machine learning (ML) are always seeking to produce improved prediction models that are able to understand the most recent data in the sector of cervical cancer. It has been shown that predictive models that are developed via the use of machine learning techniques may be of assistance in the process of cervical cancer detection (4). The Artificial Neural Network (ANN) is one of the machine learning techniques that is used the most (5).

ANN, one of the artificial intelligence methods, is a computational tool based on the properties of biological nervous systems. ANN is a data processing technique developed to solve very complex problems with the help of computers, consisting of a large number of processing elements connected to each other through weighted links, each of which has its own memory (6). It is a method of processing data on a computer that imitates the way biological neurons carry out

their functions and evaluates the connection that exists between a system's inputs and its outputs. The neuron, also known as a node, is the main component of an ANN and the primary building block of the information processing system (7). This machine learning approach has several levels, including inputs, outputs, and hidden layers. The input layer is a layer that doesn't do any computing but gets information from the outside world. The number of input and output variables is equal to the number of nodes in the input and output layers. ANN have been shown to be useful for a number of tasks, such as predicting, modeling, and classifying (8).

The Multilayer Perceptron ANN (MLPNN) is an ANN model for dealing with problems that don't follow a straight line. It is a feed-forward backpropagation network with at least one layer and at least three levels between the input and output layers (9). During the forward propagation stage, while the network's performance and error value are being computed, the relation weight values across the layers are modified to reduce the error value seen during reverse propagation (10).

Radial Based ANN (RBFNN) networks are composed of three layers: an input layer, an output layer, and a hidden layer. It is an ANN model based on neuron cells in the human nervous system. The RBFNN example's training performance becomes an interpolation issue by locating the closest result to the data in the output vector space. RBFNN structures, like ANN

structures, normally comprise of an input layer, a hidden layer, and an output layer. However, unlike other ANNs, when the data is sent from the input layer to the hidden layer, it is subjected to radial-based activation functions and a non-linear cluster analysis. The structure between the hidden layer and the output layer functions similarly to other ANN types, and the real training occurs in this layer (11).

The goal of this work was to classify cervical cancer using the open-access "Cervical Cancer Behavior Risk Data Set," to compare the predictions of MLPNN and RBFNN, and to find the risk factors for cervical cancer using these techniques.

METHODS

Dataset

The open access "Cervical Cancer Behavior Risk Data Set" data set to be used in the study can be accessed at <https://archive.ics.uci.edu/ml/datasets/Cervical+Cancer+Behavior+Risk#>. There are 72 patients in the data set used. Twenty-one of these patients were cervical cancer and 51 of them were non-cervical cancer patients.

Artificial Neural Network Models

Because of their efficiency, adaptability, and usability, artificial neural networks are the chosen solution for many predictive data mining applications. Predictive neural networks are very beneficial in applications with complicated mechanisms. In the past few years, people have

become more interested in using neural networks to solve problems that can't be solved with traditional methods. ANN has been used successfully in many medical applications. Unlike traditional spectrum analysis methods, artificial neural networks not only model signals but also create signal categorization solutions. Another benefit of artificial neural networks over traditional approaches for interpreting biological data is their speed once trained. As seen in Figure 1 shows that each layer is made up of a number of nodes.




Figure 1. ANN model's structure

MLPNN is a model that shows how an input vector maps to an output vector in a way that is not linear. It consists of a network of fundamental, interconnected neurons or nodes. Nodes are connected by weights and output signals, and the sum of each node's inputs is replaced by a simple nonlinear transfer or activation function (12).

RBFNN was created in 1908, and it became part of the history of ANN when it was used to solve the problem of filtering. The impact response

characteristics seen in biological nerve cells inspired it. RBFNN model training may be conceived of as a multi-dimensional curve-fitting technique. RBFNN models, like normal ANN architecture, are separated into three layers: input, secret layer, and output layer. Unlike traditional ANN architectures, The progression from the input layer to the hidden layer in RBFNNs is accomplished through the application of radial-based activation functions and nonlinear cluster analysis. The structure of the hidden layer and output layer is the same as in previous ANN types (13).

Statistical analysis

In order to establish whether or not the data followed a normal distribution, the Shapiro-Wilk test was carried out. Quantitative data that did not fit the normal distribution were presented as the median (minimum-maximum). The Mann-Whitney U test was performed to determine whether there was a statistically significant difference in terms of independent variables between the cervical cancer (Target variable) categories "no cervical cancer" and "have cervical cancer". $p < 0.05$ was considered statistically significant. IBM SPSS Statistics 26.0 package application was used for all analyzes.

RESULTS

Table 1 contains descriptive information for the independent variables investigated in this research. In terms of, behavior sexual risk, intention commitment, behavior personal hygiene, intention

aggregation perception vulnerability, norm fulfillment, perception severity, motivation willingness, , norm significant person, social support appreciation, social support emotionality, empowerment abilities, empowerment knowledge, motivation strength, empowerment desires variables, there is a statistically significant difference ($p < 0.05$).

Table 2 shows the values of the performance metrics obtained from the models built to predict cervical cancer in the test stage.

The accuracy, specificity, AUC, positive predictive value and negative predictive values obtained from the MLP method for the modeling test data set are 88.9%, 100.0%, 100.0%, 100.0%, and 81.8% respectively.




Figure 2. The importance values for possible risk factors

The accuracy, specificity, AUC, positive predictive value and negative predictive value values obtained from the RBF method are 92.3%, 100.0%, 96.5%, 100%, and 91.6% respectively.

In this research, the importance values of the factors associated with cervical cancer are shown in Table 3 while the values for these percentages of importance are represented in Figure 2.

Table 2. In the testing stage, performance metric values are calculated from constructed models.

Model	MLPNN	RBFNN
	Value	Value
Performance Metrics		
Accuracy (%)	88.9	92.3
Specificity (%)	100.0	100.0
AUC	1	0.965
Positive predictive value (%)	100.0	100.0
Negative predictive value (%)	81.8	91.6

AUC: Area under the ROC curve

Table 1. Descriptive statistics for quantitative independent variables

Variables	Ca cervix		p value*
	No cervical cancer	Has cervical cancer	
	Median	Median	
Behavior Sexualrisk	10 (6-10)	10 (2-10)	0.003
Behavior Eating	13 (3-15)	15 (11-15)	0.106
Behavior Personalhygiene	11 (5-15)	9 (3-15)	0.004
Intention Aggregation	10 (2-10)	6 (2-10)	0.004
Intention Commitment	15(7-15)	14 (6-15)	0.019
Attitude Consistency	7 (2-10)	8 (5-10)	0.220
Attitude Spontaneity	8 (4-10)	9 (6-10)	0.673
Norm Significantperson	5 (1-5)	1 (1-5)	0.014
Norm Fulfillment	11 (3-15)	5 (3-12)	0.001
Perception Vulnerability	10 (3-15)	5 (3-10)	0.001
Perception Severity	8 (2-10)	2 (2-7)	<0.001
Motivation Strength	15 (9-15)	11 (3-15)	0.006
Motivation Willingness	11 (3-15)	5 (3-15)	0.002
Socialsupport Emotionality	10 (3-15)	3 (3-13)	0.001
Socialsupport Appreciation	7 (2-10)	4 (2-10)	0.008
Socialsupport Instrumental	12(3-15)	9 (4-15)	0.270
Empowerment Knowledge	13 (3-15)	7 (3-13)	<0.001
Empowerment Abilities	11 (3-15)	5 (3-15)	<0.001
Empowerment Desires	13 (3-15)	6 (3-15)	<0.001

*: Mann Whitney U test

Table 3. According to MLPNN and RBFNN models, importance values of explanatory factors

Variables	MLPNN	RBFNN
Behavior Sexualrisk	0.173	0.188
Behavior Personalhygiene	0.056	0.046
Intention Commitment	0.029	0.049
Behavior Eating	0.041	0.016
Attitude Spontaneity	0.011	0.013
Intention Aggregation	0.061	0.026
Attitude Consistency	0.064	0.027
Perception Vulnerability	0.034	0.059
Norm Significantperson	0.015	0.036
Perception Severity	0.078	0.067
Norm Fulfillment	0.041	0.049
Motivation Strength	0.090	0.068
Socialsupport Appreciation	0.004	0.041
Empowerment Abilities	0.063	0.069
Socialsupport Emotionality	0.017	0.050
Motivation Willingness	0.045	0.051
Empowerment Desires	0.037	0.060
Socialsupport Instrumental	0.035	0.031
Empowerment Knowledge	0.106	0.055
Total	1.0	1.0

DISCUSSION

Cervical cancer is a serious worldwide health problem (14). Cervical cancer affects 80% of people in developing countries. By destroying the cervix, this malignancy affects the female reproductive system. Usually, it develops without causing any symptoms at first (15). The symptoms occur in the late stages of the disease, making treatment difficult, and the condition may spread to other organs.

Modern artificial intelligence approaches, such as machine learning applications, have been widely employed and beneficial in the medical health industry in recent years. It may be of considerable aid in illness diagnosis, prognosis,

and treatment, and can substantially improve the work of medical specialists, eventually improving the efficiency and quality of medical care, which has huge implications for improving medical levels, particularly in low-resource countries (16). Many cervical cancer researchers are experimenting with techniques such as machine learning. This ensures that risk variables are readily detected and examined, and that diagnostic accuracy is improved. The subject of cervical cancer classification has been the focus of a great deal of research throughout the years (17).

Nithya et al. (1) investigated cervical cancer risk factors using machine learning. There were 858 rows and 27 features in the dataset. They used the K-NN, r-part, SVM, C5.0, and Random Forest, as well as tenfold cross-validation. Parikh et al. (20) used K-NN to build a system for identifying cervical disease, selecting 25 features, 17 features, and 11 features, respectively. Tseng et al. (21) Tseng et al. utilized a dataset of 12 predictive factors from the Chung Shan Medical University Hospital Tumor Registry from 168 patients to predict cervical cancer recurrence. They compared the performance of the support vector machine (SVM), extreme machine learning (ELM), and C5.0 classifiers. According to the findings of the research, C5.0 has the greatest classification accuracy when compared to other classifiers and may also be used to pick significant independent variables (18). Machmud et al. have worked to detect cervical cancer risk using classification

algorithms such as logistic regression and Naive Bayes, and behavioral theory in social sciences. They utilized data from 72 women (22 with cervical cancer and 50 without) gathered from a questionnaire administered at the Primary Health Care Hospital in Indonesia for their research. The questionnaire includes seven questions for each of four behavior-determining theories, such as planned behavior theory and protective motive theory. The study's findings revealed that the Naive Bayes approach outperforms the logistic regression method (19). Sharma utilized a clinical dataset from the International Gynecological Cancer Society that had 237 data points and 10 characteristics. Clinical diameter, uterine body, renal pelvis, and renal primary are some of the characteristics. He provided a classification model with several choices, such as rule sets, amplification, and advanced pruning, using C5.0 to characterize the stages of cervical cancer. C5.0 with pruning option 5 exhibited the greatest accuracy in diagnosing cervical cancer stage, according to the data (20). Lu et al. studied many strategies for cervical cancer advancement and established a recommended and productive assistant pattern to forecast cervical disease. The accuracy of the Decision Tree, SVM, Logistic Regression, Multilayer Perceptron and K-NN, techniques was 77.97%, 79.25%, 82.78%, 83.16%, and 82.93% respectively (21). Wu and Zhou presented a SVM based classification model in their study to diagnose cervical cancer and

determine risk factors. In their studies, they used Recursive Feature Elimination (RFE) and Principal Component Analysis (PCA) techniques to both shorten the processing time and eliminate unimportant features. Thus, they identified the ten most important risk factors for the dataset with 32 features and four target variables. Since there was an imbalance problem in the data set used, the authors applied the balancing process to the data set by using the oversampling technique. Then, three SVM-based approaches were applied for the four target variables, respectively, and when the results were compared, it was shown that the SVM, PCA method was superior to the others (22). Abdoh et al. proposed a technique based on oversampling, RFE, PCA and random forests (RF) for cancer diagnosis. The simulation results show that the proposed technique can be used in the diagnosis of cervical cancer. Rayavarapu and Krishna used a deep neural network for cervical cancer prediction. Deng et al. The performance of XGBoost SVM and RF techniques in cervical cancer classification was investigated. As a result of the study, it has been seen that XGBoost and RF techniques have better performance than SVM (3). Hyeon et al. used a pre-trained convolutional neural network (CNN) and several machine learning classifiers as feature extractors to classify cell images as normal and abnormal. Logistic Regression, Random Forest, AdaBoost and SVM, which are machine learning classifiers, were used in the study. Studies were carried out in MATLAB

software. At the end of the studies, the support vector machine achieved the highest performance with an F1 score of 78% (23).

The goal of this research was to evaluate classification predictions using MLPNN and RBFNN from ANN models using an open-source "Cervical Cancer Behavior Risk" dataset.

An artificial neural network is a mathematical model that solves classification and prediction problems by using the control and functional components of artificial neural networks. Input and output layers, as well as hidden layers that change input to output, make up neural networks. The architecture of an artificial neural network may be constructed in two stages: training and testing, when it is utilized to forecast any illness. The weights of the connections between neurons are fixed once the ANN model has been trained with the given dataset. Second, the model under consideration is validated in order to classify a new data set. Several parameters are used to assess the performance of the produced models (24).

In this research, the RBFNN model performed better than the MLPNN model in predicting the classification of cervical cancer according to performance criteria. During the test stage, the performance measures accuracy, specificity, AUC, negative predictive value, and positive predictive value obtained from the RBFNN method were 92.3, 100.0, 0.965, 91.6, and 100.0 respectively. The three most significant risk variables related with cervical cancer were

assessed in the RBFNN model as behavior sexual risk, empowerment abilities, and motivation strength.

CONCLUSION

As a result, using multi-layer perceptron and radial-based artificial neural network models, this framework estimates various factors (explanatory variables) that may be related to cervical cancer. In light of the obtained results, the applicability of artificial intelligence methods in the classification problem of interest is demonstrated. These models have established the significant levels of potential cervical cancer risk variables for preventive medication.

Ethics Committee Approval: Ethics committee approval is not required in this study.

Peer-review: Externally peer-reviewed.

Author Contributions:

Concept: İBÇ, ZK. Design: İBÇ, ZK. Literature search: İBÇ, ZK. Data Collection and Processing: İBÇ, ZK. İB. Analysis or Interpretation: İBÇ, ZK. Written by: İBÇ, ZK.

Conflict of Interest: The authors declared no conflict of interest

Financial Disclosure: The authors declared that this study has not received no financial support.

REFERENCES

1. Bruni L, Albero G, Serrano B, Mena M, Gomez D, Munoz J, et al. Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report. 2019.
2. Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda G-A, Zhou Y, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation. *Frontiers in public health*. 2021;8:552028.
3. Eyupoğlu C. A New Cervical Cancer Diagnosis Method Based on Correlation-Based Trait Selection, Genetic Search, and Random Forests Techniques. *European Journal of Science and Technology*. 2020;19:263-71.
4. Singh HD. *Diagnosis of Cervical Cancer using Hybrid Machine Learning Models*: Dublin, National College of Ireland; 2018.
5. Sokouti B, Haghypour S, Tabrizi AD. A framework for diagnosing cervical cancer disease based on feedforward MLP neural network and ThinPrep histopathological cell image features. *Neural Computing and Applications*. 2014;24(1):221-32.
6. Oztemel E. *Artificial neural networks*, Daisy Publishing. First Edition. Istanbul;2003.p.48.
7. Siddique R, Aggarwal P, Aggarwal Y. Prediction of compressive strength of self-compacting concrete containing bottom ash using artificial neural networks. *Advances in engineering software*. 2011;42(10):780-6.
8. Haykin S. *Neural Networks, a comprehensive foundation*, Prentice-Hall Inc. Upper Saddle River, New Jersey. 1999;7458:161-75.

9. Batar H. Classification of EEG signals with artificial neural networks using wavelet analysis methods. Kahramanmaras: Institute of science, Master Thesis. 2005.
10. Arı A, Berberler ME. Interface Design for the Solution of Prediction and Classification Problems with Artificial Neural Networks. 2017;1(2):55-73.
11. Golafshani EM, Behnood A. Application of soft computing methods for predicting the elastic modulus of recycled aggregate concrete. Journal of cleaner production. 2018;176:1163-76.
12. Orhan U, Hekim M, Ozer M, et al. Discretization approach to EEG signal classification using Multilayer Perceptron Neural Network model. 2010 15th National Biomedical Engineering Meeting; 2010: IEEE.
13. Kaynar O, Gormez Y, Işık YE, Demirkoparan F, et al. Intrusion Detection with Radial Based Artificial Neural Networks Trained with Different Clustering Algorithms. International Artificial Intelligence and Data Processing Symposium; 2016.
14. Saha A, Chaudhury AN, Bhowmik P, Chatterjee R. Awareness of cervical cancer among female students of premier colleges in Kolkata, India. Asian Pac J Cancer Prev. 2010;11(4):1085-90.
15. Priya NS. Cervical cancer screening and classification using acoustic shadowing. International Journal of innovatibe Research in Computer and Communication Engineering. 2013;1(8):1676-9.
16. Wu M, Yan C, Liu H, Liu Q. Automatic classification of ovarian cancer types from cytological images using deep convolutional neural networks. Bioscience reports. 2018;38(3).
17. Akter L, Islam M, Al-Rakhami MS, Haque M. Prediction of cervical cancer from behavior risk using machine learning techniques. SN Computer Science. 2021;2(3):1-10.
18. Tseng CJ, Lu CJ, Chang CC, Chen GD. Application of machine learning to predict the recurrence-proneness for cervical cancer. Neural Computing and Applications. 2014;24(6):1311-6.
19. Machmud R, Wijaya A. Behavior determinant based cervical cancer early detection with machine learning algorithm. Advanced Science Letters. 2016;22(10):3120-3.
20. Sharma S. Cervical cancer stage prediction using decision tree approach of machine learning. International Journal of Advanced Research in Computer and Communication Engineering. 2016;5(4):345-8.
21. Lu J, Song E, Ghoneim A, Alrashoud M. Machine learning for assisting cervical cancer diagnosis: An ensemble approach. Future Generation Computer Systems. 2020;106:199-205.
22. Wu W, Zhou H. Data-driven diagnosis of

- cervical cancer with support vector machine-based approaches. IEEE Access. 2017;5:25189-95.
23. Hyeon J, Choi HJ, Lee KN, Lee BD, et al. Automating papanicolaou test using deep convolutional activation feature. 18th IEEE international conference on Mobile Data Management (MDM); 2017.
24. Nasser IM, Abu-Naser SS. Lung Cancer Detection Using Artificial Neural Network. J. Eng. Technol. 2019;3(3):17-23.

ARAŞTIRMA MAKALESİ/ RESEARCH ARTICLE

A retrospective evaluation of the prevalence of anti- *Echinococcus granulosus* in patients with suspected cystic echinococcosis at İnönü University Faculty of Medicine Turgut Özal Medical Center between 2018 and 2022

Türkan Mutlu Yar¹(ID), Tülay Aksoy²(ID), İpek Balıkçı Çiçek³(ID), Metin Atambay¹(ID)

1Department of Parasitology, Faculty of Medicine, İnönü University, Malatya, Turkey

2Department of Parasitology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey

3Department of Biostatistics, Faculty of Medicine, İnönü University, Malatya, Turkey

Received: 11 September 2022, Accepted: 27 September 2022, Published online: 31 December 2022

© Ordu University Institute of Health Sciences, Turkey, 2022

Abstract

Objective: Cystic echinococcosis (CE) is a common zoonotic disease in the world, caused by the larval form of *Echinococcus granulosus* got lodged in various organs in both animals and humans. This study aimed to retrospectively examine ELISA test results in patients who applied to Inonu University Faculty of Medicine Parasitology Department with the suspicion of cystic echinococcosis.

Methods: The study was performed via ELISA to detect the presence of anti - *E. granulosus* immunoglobulin G (IgG) antibodies in the patients who came to the Parasitology Department with the suspicion of CE between January 2018 and June 2022.

Results: It was observed that *E. granulosus* antibody was detected as positive in 1353 (63.7%) and negative in 772 (36.3%) of the serum samples of 2128 patients admitted with the suspicion of hydatid cyst. Of 1353 cases with positive anti-*E. granulosus* IgG antibodies, 700 (51.74%) were females and 653 (48.26%) were males.

Conclusion: The retrospective study presented is intended to raise awareness of public health. As in Turkey, it is necessary to inform the public about CE in Malatya region, to draw the attention of the authorities to this issue, and to establish protection and control programs quickly. And it is recommended that these retrospective studies should be repeated to determine the importance of prevalence from time to time.

Key Words: Cystic Echinococcosis, *Echinococcus granulosus*, ELISA, Malatya

İNÖNÜ ÜNİVERSİTESİ TIP FAKÜLTESİ TURGUT ÖZAL TIP MERKEZİNE 2018-2022 YILLARI ARASINDA KİSTİK EKİNOKOKKOZİS ŞÜPHESİ İLE GELEN HASTALARDA ANTI - *Echinococcus granulosus* PREVELANSININ RETROSPEKTİF OLARAK DEĞERLENDİRİLMESİ

Özet

Amaç: Kistik ekinokokkozis (KE), *Echinococcus granulosus*'un larva formunun hem hayvanlarda, hem insanlarda çeşitli organlara yerleşmesiyle oluşan, dünyada yaygın olarak görülen zoonotik bir hastalıktır. Bu çalışma da, İnönü Üniversitesi Tıp Fakültesi Parazitoloji Anabilim dalına kistik ekinokokkozis şüphesi ile başvuran hastalarda ELİSA test sonuçlarının geriye yönelik olarak incelenmesi amaçlanmıştır.

Yöntem: Çalışma 2018 Ocak - 2022 Haziran tarihleri arasında Parazitoloji ABD'na KE şüphesi ile gelen hasta anti - *E. granulosus* immunoglobulin G (IgG) antikorlarının varlığını saptamak için ELISA yöntemi ile çalışılmıştır..

Bulgular: Kist hidatik şüphesi ile gelen 2128 hastanın serum örneklerinden 1353'ünde (%63.7) *E. granulosus* antikorunun pozitif olarak tespit edildiği 772'sinde (%36.3) ise negatif olarak saptandığı gözlemlenmiştir. Anti - *E. granulosus* IgG antikor pozitif olan toplam 1353 olgudan 700'ü (%51.74) kadınlardan, 653'ü (%48.26) ise erkeklerden oluşmaktadır..

Sonuç: Sunulan retrospektif çalışma halk sağlığına yönelik bir farkındalık yaratmak amacıyla düşünülmüştür. Türkiye'de olduğu gibi Malatya yöresinde halkın KE hakkında bilgilendirilmesi, yetkililerin konuya dikkatlerinin çekilmesi, koruma ve kontrol programlarının hızlı bir şekilde oluşturulması gerekmektedir. Bu retrospektif çalışmaları prevalansın önemini belirlemek için tekrar edilmesi önerilmektedir.

Anahtar Kelimeler: Kistik Echinococcosis, *Echinococcus granulosus*, ELISA, Malatya

Suggested Citation: Yar TM, Aksoy T, Balıkçı Çiçek I, Atambay M. A retrospective evaluation of the prevalence of anti-*Echinococcus granulosus* in patients with suspected cystic echinococcosis at İnönü University Faculty of Medicine Turgut Özal Medical Center between 2018 and 2022. ODU Med J, 2022;9(3): 94-103



Address for correspondence/reprints:

Türkan Mutlu Yar

Telephone number: +90 (530) 349 32 06**E-mail:** mutluyarr@gmail.com

INTRODUCTION

Cystic echinococcosis (CE) is a disease caused by the larval forms (metacestode) of *Echinococcus granulosus* and the development of larvae in all tissues and organs, including the liver and lungs, as a result of the accidental ingestion of eggs by humans (1). CE is an important public health problem that is more common in societies where agriculture and animal husbandry are common all over the world. Humans are accidental intermediate hosts for this parasite, where dogs and canines are the definitive hosts (2).

The disease is seen worldwide, being endemic in countries dealing with animal husbandries, such as Mediterranean countries, South America, Central Asia and Russia. It is more common in Central Anatolia and Eastern Anatolia regions in our country. Carnivores are definitive hosts, and humans and some mammals (sheep, goats, camels, horses) are intermediate hosts for *E. granulosus*(3). The clinic of the patients varies according to the size of the cyst, the organ in which it is located, the eruption of the cyst and the immunological response. Small, well-encapsulated cysts may

calcify and remain asymptomatic for years. While liver and lung are most commonly involved, it may rarely be involved in organs such as muscles, bones, kidneys, brain, and spleen. Most of the cysts are asymptomatic and may regress spontaneously (4,5). Currently, four options are recommended for cyst treatment.

1. Percutaneous treatment of hydatid cysts with PAIR technique, 2. Surgery, 3. Anti-infective drug treatment, 4. Watch and wait (6).

The exact prevalence is unknown because most of CE cases are asymptomatic, clinical signs are uncharacteristic, and the cyst development is very slow. When serological methods such as enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody test (IFAT), indirect hemagglutination test (IHA), and Western blot (WB) and DNA-based molecular methods are combined with non-invasive imaging techniques, they have been the preferred approaches for monitoring and surveillance in diagnosis and treatment as well as during control programs (7).

This study was performed to retrospectively evaluate the distribution of anti-*E. granulosus* antibodies in patients who came to the parasitology laboratory with the suspicion of CE between January 2018 and June 2022.

METHODS

The study was conducted with the retrospective evaluation of the data by taking blood samples

from the patients who came to the Inonu University Faculty of Medicine Parasitology laboratory with the suspicion of CE between January 2018 and June 2022.

Anti-*E. granulosus* antibodies were analyzed by ELISA (Enzyme-linked immunosorbent assay) method in serum samples of 2128 patients who came to the laboratory. The blood taken from the patients was first centrifuged and separated into serum. ELISA method was studied following the kit procedure of the manufacturer (NOVATEC). The results were read in ELISA reader at a wavelength of 450 nm, and the values obtained were analyzed according to the ratios given in the kit's user manual and evaluated as positive and negative.

Statistical analysis

Data were presented as median (min-max), mean (standard deviation), and number (percent). Compliance with the normal distribution was tested using the Kolmogorov-Smirnov and Shapiro-Wilk tests. Pearson Chi-square and Mann Whitney U test were used where appropriate for statistical analysis. A value of $p < 0.05$ was considered statistically significant. IBM SPSS Statistics 26.0 program was used in the analysis.

RESULTS

The study evaluated the presence of anti-*E. granulosus* IgG antibody in the serum samples of 2128 patients who applied to Turgut Özal Medical Center Parasitology Laboratory with suspicion between January 2018 and June 2022. It was

observed that *E. granulosus* antibody was detected as positive in 1353 (63.7%) and negative in 772 (36.3%) of the serum samples of the subjects analyzed within the scope of the study. The distribution of the variables in the study was given in Table 1.

The distribution of the subjects in the study by years was presented in Table 2 and Figure 1. When Table 2 was analyzed, it was observed that 232 (30.05%) were negative and 450 (33.26%) were positive in 2018, 164 (21.24%) were negative and 356 (26.31%) were positive in 2019, 149 (19.30%) were negative and 184 (13.60%) were positive in 2020, 146 (18.91%) were negative and 247 (18.26%) were positive in 2021, and 81 (10.49%) were negative and 16 (8.57%) were positive in 2022. When the distribution of anti-*E. granulosus* IgG antibodies by years was examined, it was detected that the highest positivity rate was in 2018, and the lowest positivity rate was in 2022. Moreover, there is a statistically significant association with respect to anti-*E. granulosus* IgG antibody by years ($p < 0.05$).

The distribution of the presence of anti-*E. granulosus* IgG antibody by gender was given in Table 3 and Figure 2. When the results in Table 3 were examined, 700 (51.74%) were women and 653 (48.26%) were men of 1353 patients with positive anti-*E. granulosus* IgG antibodies. Moreover, there was no statistically significant association with gender in terms of the presence of anti-*E. granulosus* IgG antibody ($p > 0.05$). When

the distribution of the positivity rate over the years was analyzed, the positivity rate showed a decreasing trend over the years but started to rise again in 2021.

The distribution of the presence of anti-*E. granulosus* IgG antibodies according to different departments was given in Table 4 and Figure 3. Of the subjects who were positive for anti-*E. granulosus* IgG antibody, 41 (3.03%) were in infection, 350 (25.87%) were in gastroenterology, 517 (38.21%) were in general surgery, 45 (3.33%) were in hepatology, 157 (11.60%) were in liver transplantation, 22 (1.63%) were in proctology, 11 (0.81%) were in examination and 210 (15.52%) were in pediatrics department. Accordingly, the anti-*E. granulosus* IgG antibody positivity rate was the highest in patients who come to the general surgery department. Moreover, there was a statistically significant correlation according to the

departments in terms of the presence of anti-*E. granulosus* IgG antibody ($p < 0.05$).

The results of the analysis according to the age and the presence of anti-*E. granulosus* IgG antibody were presented in Table 5. There was a statistically significant difference in age in terms of the presence of anti-*E. granulosus* IgG antibody ($p < 0.05$).

The distribution of years by gender in case of positive anti-*E. granulosus* IgG antibody was given in Table 6. According to the findings in the table, the year with the highest positivity rate in both women and men was 2018, and the year with the lowest was 2022.

The distribution of years by departments in case of positive anti-*E. granulosus* IgG antibody was given in Table 7.




Figure 1. Distribution graph of the presence of anti- *E. granulosus* IgG antibody by years

Table 1. Variables in the study

Variables	Categories	Number	Percentage (%)
Value	Negative	772	36.3
	Positive	1353	63.7
Year	2018	682	32.0
	2019	520	24.4
	2020	335	15.7
	2021	393	18.5
	2022	198	9.3
Gender	Female	1122	52.7
	Male	1006	47.3
Department	Infection	92	4.3
	Gastroenterology	510	24.0
	General surgery	759	35.7
	Hepatology	105	4.9
	Liver Transplantation	234	11.0
	Proctology	31	1.5
	Examination	17	0.8
	Pediatrics	380	17.9

Table 2. Distribution of anti-*E. granulosus* IgG antibody by years

		Negative [n(%)]	Positive [n(%)]	p value*
Years	2018	232 (30.05)	450 (33.26)	0.001
	2019	164 (21.24)	356 (26.31)	
	2020	149 (19.30)	184 (13.60)	
	2021	146 (18.91)	247 (18.26)	
	2022	81 (10.49)	116 (8.57)	

*Pearson Chi-square test

Table 3. Distribution of anti-*E. granulosus* IgG antibody by gender

		Negative [n(%)]	Positive [n(%)]	p value*
Gender	Female	420 (54.40)	700 (51.74)	0.236
	Male	352 (45.60)	653 (48.26)	

*:Pearson Chi-square test

Table4. Distribution of anti-*E. granulosus* IgG antibody by departments

		Negative [n(%)]	Positive [n(%)]	p value*
Department	Infection	51 (6.61)	41 (3.03)	<0.001*
	Gastroenterology	158 (20.47)	350 (25.87)	
	General Surgery	242 (31.35)	517 (38.21)	
	Hepatology	59 (7.64)	45 (3.33)	
	Liver Transplantation	77 (9.97)	157 (11.60)	
	Proctology	9 (1.17)	22 (1.63)	
	Examination	6 (0.78)	11 (0.81)	
	Pediatrics	170 (22.02)	210 (15.52)	

*Pearson Chi-square test




Figure 2. Distribution graph of the presence of anti-*E. granulosus* IgG antibody by gender




Figure 3. Distribution graph of the presence of anti-*E. granulosus* IgG antibody by departments

Table 5. Analysis table of age according to presence of anti- *E. granulosus* IgG antibody

	Value		p value*
	Negative	Positive	
	Median (Minimum-Maximum)	Median (Minimum-Maximum)	
Age	46(1-98)	39(3-90)	0.003

*: Mann Whitney U test

Table 6. Distribution of years by gender in case of positive anti-*E. granulosus* IgG antibody

Variables		Gender			
		Female		Male	
		Number	Percentage (%)	Number	Percentage (%)
YEAR	2018	254	36.3	196	30.0
	2019	171	24.4	185	28.3
	2020	93	13.3	91	13.9
	2021	122	17.4	125	19.1
	2022	60	8.6	56	8.6

Table 7. Distribution of years by departments in case of positive anti-*E. granulosus* IgG antibody

Variables		Department							
		Infection [n(%)]	Gastroenterology (n[n(%)])	General Surgery [n(%)]	Hepatology [n(%)]	Liver Transplantation [n(%)]	Proctology [n(%)]	Examination [n(%)]	Pediatrics [n(%)]
Year	2018	7 (17.07)	110 (31.43)	219 (42.36)	14 (31.11)	37 (23.57)	6 (27.27)	7 (63.64)	50 (23.81)
	2019	10 (24.39)	85 (24.29)	154 (29.79)	12 (26.67)	30 (19.11)	2 (9.09)	4 (36.36)	59 (28.10)
	2020	9 (21.95)	107 (30.57)	2 (0.39)	2 (4.44)	27 (17.20)	5 (22.73)	0 (0.00)	32 (15.24)
	2021	14 (34.15)	29 (8.29)	97 (18.76)	7 (15.56)	46 (29.30)	7 (31.82)	0 (0.00)	47 (22.38)
	2022	1 (2.44)	19 (5.43)	45 (8.70)	10 (22.22)	17 (10.83)	2 (9.09)	0 (0.00)	22 (10.48)

DISCUSSION

CE is one of the important zoonotic infections that cause serious health problems and deaths as well as economic losses in humans. It is common in underdeveloped and developing countries due to factors such as hygiene rules, cultural level of the people, uncontrolled and illegal slaughter of butchery animals, the high number of stray dogs, and the discharge of infected internal organs into the environment without destruction (8).

According to serological data in studies conducted in our country, the probability of CE is 3.45% in İzmir (9), 14.6% in Ayon (10), 0.4% in Manisa (11) and 54.1% in Ankara (12). In a retrospective study conducted by Yazar et al. across the country, the rates of CE were reported

13.13% in the Marmara region, 16.94% in the Aegean region, 16.09% in the Mediterranean region, 38.57% in the Central Anatolia region, 5.70% in the Black Sea region, 6.80% in the Eastern Anatolia region, and 2.75% South-Eastern Anatolia region (13).

In our study, anti-*E. granulosus* antibodies were observed in 1353 (63.7%) of 2128 patients admitted with the suspicion of CE between 2018 and 2022, according to serological data.

An important finding in the studies is that the infection is seen higher in women. A higher prevalence was reported in women in previous studies on CE (8, 14). In another study, in which blood samples from 2642 patients were evaluated for CE with ELISA method, 31.9% of men and

29% of women were positive out of 801 (30.3%) seropositive patients (15). It was observed in a study evaluating CE according to hospital records in Kayseri between 1999 and 2004 that 699 subjects were positive, of whom 330 (42.2%) were male and 369 (57.8%) were female (16).

In our study, when the results were assessed with respect to gender, 700 (51.74%) were female and 653 (48.26%) were male, of 1353 patients with positive anti-*E. granulosus* IgG antibody. In addition, there is no statistically significant association with gender in terms of the presence of anti-*E. granulosus* IgG antibody ($p>0.05$).

In a study in which patients admitted with a pre-diagnosis of CE in Çorum were evaluated radiologically, biochemically and serologically, it was found that most of the patients who were found to be seropositive were from the general surgery outpatient clinic and were followed by the infection and gastroenterology outpatient clinics (14). In a study conducted in Kayseri, it was observed that they applied to general surgery, gastroenterology, chest diseases, infectious diseases, urology, pediatrics and other polyclinics, respectively. (7).

The distribution of the presence of anti-*E. granulosus* IgG antibodies according to different clinics in our study was that 41(3.03%) of positive subjects were in infection, 350(25.87%) were in gastroenterology, 517(38.21%) were in general surgery, 45(3.33%) were in hepatology, 157(11.60%) were in liver transplantation,

22(1.63%) were in proctology, 11(0.81%) were in examination and 210(15.52%) were in pediatrics. Accordingly, the positivity rate of anti-*E. granulosus* IgG antibody in patients who come to the general surgery department is the highest. Moreover, there is a statistically significant association according to the departments in terms of the presence of anti-*E. granulosus* IgG antibody ($p<0.05$).

When the publications made in our country were analyzed, Karaman et al. (17) detected the anti-*E. granulosus* IgG antibody positivity rate as 40.5% by IFA and indirect hemagglutination (IHA) method in Malatya and its surroundings between 1999 and 2002. Karaman et al. (18) evaluated the positivity rate as 34.6% in Kars city center and its villages in 2005, using IHA and IFA methods. Çetinkaya et al. (19) assessed the positivity rate as 24.7% with at least one of IHA, IFA and western blot methods between 1999 and 2010. Beyhan et al. (8) evaluated the positivity rate as 22.7% in Ankara and its surroundings between 2009 and 2013. Ertabak et al. (20) determined the positivity rate as 32% using ELISA method in Aydın province between 2005 and 2017.

In our study, the distribution of anti-*E. granulosus* IgG antibodies according to years in the patients who came to Turgut Özal Medical Center Parasitology laboratory between 2018 and 2022 and analyzed with ELISA method was examined, it was observed that the highest positivity rate was in 2018 (30.05%), and the lowest positivity rate

was in 2022. Moreover, there was a statistically significant association in terms of anti-*E. granulosus* IgG antibody by years ($p<0.05$).

Ethics Committee Approval: Approval was obtained from the İnönü Universty scientific research and publication ethics committee (Health sciences non-invasive clinical research ethics committee) for the study to be carried out.

Peer-review: Externally peer-reviewed.

Author Contributions:

Concept: TMY Design: TMY, TA. Literature search: TMY, TA. Data Collection and Processing: TMY, TA, MA, İBÇ. Analysis or Interpretation: İBÇ. Written by: TMY, MA

Conflict of Interest: The authors declared no conflict of interest

Financial Disclosure: The authors declared that this study has not received no financial support.

REFERENCES

1. Arslan ÖM, Mor N, Bedir H. Seropozitifity of anti- *Echinococcus granulosus* in patients with of clinical prediagnosis cystic *Echinococcus* at Kafkas University health research and application hospital. *T.Parazitol. Derg.* 2022; 46(2):129-32.
2. Alver O, Payaslıoğlu MA, Özakın C, Esen S. Laboratory results of cystic *Echinococcus* in 2017-2018. *T.Parazitol. Derg.* 2021; 45(3): 207-210.
3. Aktar SG, Ayaydın Z and et al. Retrospective evaluation of cases with the pre-diagnosis of cystic *echinococcosis* admitted to the microbiology laboratory of Diyarbakır health sciences Gazi Yaşargil training and research hospital between 2014 and 2017. *T.Parazitol. Derg.* 2020; 44(4): 207-10.
4. Altıntaş N. Pasttopresent: *echinococcosis* in Turkey. *Acta Trop.*2003; 85: 105-12.
5. Amman R, Eckert J. *Cestodes: Echinococcus*. *Gastroenterology clinics of North american* 1996; 25: 655-89.
6. Çelik T, Alev C, Akgün S, Güldoğan E, Şahin F. A retrospective evaluation of serobgical results of cystic *echinococcosis* suspected cases admitted to Adıyaman training and research hospital between 2013-2020. *T.Parazitol. Derg.* 2022; 46(2): 140-4.
7. Yürük M, Yaman O, Sivcan E, Erdoğan E. Retrospective deterrmination of the prevelense of anti- *Echinococcus granulosus* antibodies in cystic *Echinococcosis* Pre- diagnosed patients at Erciyes University Faculty of Medicine. *T.Parazitol. derg* 2022;46/2: 133-9.
8. Beyhan YE, Babür C, Mungan M, Özkan Taylan A, Evaluation of cystic *echinococcosis* suspected patients applied to national parasitology reference laboratory of public health Institution of Turkey between 2009-2013. *Turkey Parazitol Derg*2015;39:17-21.
9. Altıntaş N, Yazar S, Yolasığmaz A, Akısü Ç, Şakru N, Karacasu F, et al. A serum epidemiological study of cystic *echinococcosis*

- in İzmir and its surrounding area. Turkey helminthologia 1999; 36: 19-23.
10. Çetinkaya Z, Çiftçi IH, Demirel R, Altındış M, Ayaz E. A sero- epidemiological study on cysticechinococcosis in Mid western region of Turkey. Saudi Med J 2005;26: 350-1.
 11. Kilimcioğlu AA, Özkol M, Bayındır P, Girginkardeşler N, Ostan I, ok uz. The value of ultrasonography alone in screening surveys of cystic echinococcosis in children in Turkey. Parasitol Int 2006; 55: 273-5.
 12. Eşgin M, Aktaş M, Coşkun Ş, The investigation of antibody presence in the sera of patients with a suspicion of cystic echinococcosis by using in direct hemagglutination test(IHA) Turkey Parasitol Derg 2007;31: 283-7.
 13. Yazar S, Taylan Özkan A, Hökelek M, Polat E, Yılmaz, Özbilge H, et al. Cysticechinococcosis in Turkey from 2001-2005. Turkey Parasitol Derg 2008; 32: 208-20.
 14. Güreşer AS, Özcan O, Özürel L, Boyacıoğlu Zİ, Taylan Özkan HA. Evaluation of Radiological, Biochemical and serological parameters of patients prediagnosed as cystic Echinococcosis in Çorum, Turkey Mikrobiyol Bul 2015; 49: 231-49.
 15. Taş Cengiz Z, Yılmaz H, Beyhan YE, Kotan MC, Çobanoğlu V, Ekici A, et al. Cystic Echinococcosis seropositivity in the blood samples sent to parasitology laboratory of in the blood samples sent to parasitology laboratory of Yüzüncü Yıl University Medical Faculty between 2005-2013. Retrospective Assessment Turkey Parasitol. Derg 2015; 39:209-11.
 16. Yazar S, CysticEchinococcosis in Kayseri during the last six years. Turkey Parasitol derg 2005;29:241-3.
 17. Karaman Ü, Daldal N, Atambay M, Aycan MÖ. Serological results of cases with a presumptive diagnosis of hydatid cyst during 1999-2002 in the İnönü University Medical Faculty, Malatya. İnönü Univ. Tıp Fak Derg 2002; 9: 233-5.
 18. Karaman Ü, Miman Ö, Kara M, Gıcık Y, Aycan ÖM, Atambay M. Hydatidcyst prevalence in the region of Kars. Turkey Parasitol Derg 2005;29: 238-40.
 19. Çetinkaya Ü, Hamamcı B, Kaya M, Gücüyetmez S, Kuk S, Yazar S, et al. Investigation of Anti- Echinococcus granulosus antibodies in patients with suspected cystic Echinococcosis Turkey Parasitol, Derg 2012; 36: 57-60.
 20. Ertabaklar H, Yıldız İ, Malatyalı E, Tileklioğlu E, Çalışkan SÖ, Ertuğ S. Retrospective Analysis of cystic echinococcosis results in Aydın Adnan Menderes University training and research hospital parasitology Laboratory between 2005 and 2017. TurkeyParasitolDerg 2019;43: 118-22.

ARAŞTIRMA MAKALLES/ RESEARCH ARTICLE

Detection of Coronary Heart Disease by Data Mining Methods Using Clinical Data

Burak Yağın¹([ID](#))¹Department of Biostatistics and Medical Informatics, Faculty of Medicine, İnönü University, Malatya, TurkeyReceived: 03 October 2022, Accepted: 19 December 2022, Published online: 31 December 2022
© Ordu University Institute of Health Sciences, Turkey, 2022**Abstract**

Objective: The major cause of death worldwide is anticipated to continue to be heart disease, one of the most prevalent diseases in the globe. Therefore, the aim of this study is to classify and predict coronary heart disease using the Random forest (RF) method, which is one of the predictive algorithms of data mining.

Methods: The dataset was divided into 80% training and 20% test sets to avoid bias. Then the model was trained on the training set and tested on the test set. In the study, the RF algorithm was used for the classification of coronary heart disease. The performance of the RF model was evaluated with balanced accuracy, accuracy, sensitivity, F1-score, negative predictive value, positive predictive value, specificity, and confusion matrix results.

Results: The data set included clinical data of 1190 patients, 281 (23.6%) female, and 909 (76.4%) males. Based on the results from the RF model, balanced accuracy, accuracy, sensitivity, F1-score, negative predictive value, positive predictive value, and specificity for heart disease were 0.945, 0.945, 0.920, 0.941, 0.931, 0.963, and 0.968, respectively.

Conclusion: According to the performance measures obtained in the test set for coronary heart disease (CHD), the RF model performed well. As a result, the proposed model can provide clinicians with clinical decision support for the preliminary diagnosis of CHD patients.

Key Words: Heart disease, artificial intelligence, data mining, random forest, parameter optimization

Klinik Veriler Kullanılarak Veri Madenciliği Yöntemleriyle Koroner Kalp Hastalığının Tespiti**Özet**

Amaç: Dünya çapında en önemli ölüm nedeninin, dünyadaki en yaygın hastalıklardan biri olan kalp hastalığı olmasının devam etmesi beklenmektedir. Bu nedenle bu çalışmanın amacı, veri madenciliğinin tahmin edici algoritmalarından biri olan Rastgele Orman (RF) yöntemini kullanarak koroner kalp hastalığının sınıflandırılması ve tahmin edilmesidir.

Yöntemler: Modelin doğrulaması için veri seti %80 eğitim ve %20 test setlerine bölünmüştür. Daha sonra model eğitim seti üzerinde eğitilmiş ve test seti üzerinde test edilmiştir. Çalışmada koroner kalp hastalığı sınıflandırması için RF algoritması kullanılmıştır. RF modelinin performansı, dengeli doğruluk, doğruluk, duyarlılık, F1-skor, negatif tahmin değeri, pozitif tahmin değeri, seçicilik ve karışıklık matrisi sonuçları ile değerlendirildi.

Bulgular: Veri seti 281 (%23.6) kadın ve 909 (%76.4) erkek olmak üzere 1190 hastanın klinik verilerini içermektedir. RF modelinden elde edilen sonuçlara göre kalp hastalığı için dengeli doğruluk, doğruluk, duyarlılık, F1-skor, negatif tahmin değeri, pozitif tahmin değeri ve seçicilik sırasıyla 0.945, 0.945, 0.920, 0.941, 0.931, 0.963 ve 0.968 idi.

Sonuç: Koroner kalp hastalığı (KKH) için test setinde elde edilen performans ölçütlerine göre, RF modeli iyi performans gösterdi. Sonuç olarak önerilen model, klinisyenlere KKH hastalarının ön tanısı için klinik karar desteği sağlayabilir.

Anahtar Kelimeler: Kalp hastalığı, kardiyovasküler hastalık, yapay zeka, veri madenciliği, rastgele orman

Suggested Citation: Yağın B. Detection of Coronary Heart Disease by Data Mining Methods Using Clinical Data. ODU Med J, 2022;9(3): 104-109

Copyright@Author(s) - Available online at <https://dergipark.org.tr/pub/odutip>[Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.](#)**Address for correspondence/reprints:****Telephone number:** +90 (506) 777 14 06

Burak Yağın

E-mail: burak.yagin@inonu.edu.tr

INTRODUCTION

One of the most frequent reasons for a heart attack is a clogged coronary artery. The primary cause of death is still heart disease. For the best treatment, the prevention of poor clinical outcomes, and mortality, early diagnosis of this condition is essential. The risk factors for cardiovascular disease (CVD) include male gender, advanced age, inactivity, low education, unemployment, economic situation, psychological state, and hypertension. Heart attack risk can be decreased by eating a diet high in salt, consuming less fat, cholesterol, alcohol, and smoking, exercising frequently, and decreasing weight (1-3).

Artificial intelligence (AI) methods are often used to quickly, and accurately diagnose heart disease (4). AI is a technology that improves performance and productivity in the field by automating processes or tasks that previously required manpower. AI makes it possible for machines to learn from experience, adapt to new inputs, and perform human-like tasks. Using AI technologies, computers can be trained to perform specific tasks by processing large amounts of data and recognizing patterns in the data. These technologies are used in medicine for purposes such as classifying and predicting diseases and determining the most important factors that cause diseases (5-10).

One of the fastest expanding subfields of AI is data mining. Data mining is the process of

analyzing large data sets to reveal hidden critical decision-making information for future analysis. The amount of data obtained in the field of medicine is increasing day by day. Predictive algorithms of data mining can be used to extract useful, important, and relevant information from these data for the relevant situation (11-13).

Data mining methods are needed both in estimating heart attacks and other heart diseases and in determining risk factors. From this point of view, in this study, using the risk factors related to heart attack, a successful model is created to predict the disease by classifying it quickly and accurately with minimum error.

METHODS

Dataset

The heart disease dataset from the IEEE Data Port database (<https://ieee-dataport.org/open-access/heart-disease-datasetcomprehensive#files>) was obtained. The data set included clinical data of 1190 patients, 281 (23.6%) female, and 909 (76.4%) male (14).

Data processing and modeling

The dataset was divided into 80% training and 20% test sets to avoid bias. Then the model was trained on the training set and tested on the test set. Then, 5-fold cross-validation was used as a resampling method. Balanced accuracy, accuracy, sensitivity, F1-score, negative predictive value, positive predictive value, and specificity values were calculated to evaluate the performance of the model.

Random Forest (RF)

RF algorithm, which can be used for classification and regression analysis, is an ensemble classification method. The goal of this community classifier is to improve classification accuracy by building many decision trees. During the training phase, RFs create various decision trees and labels based on the majority. The main distinction between RFs and decision tree methods is that identifying the root node and splitting the nodes essentially work arbitrarily. The RF approach is taken into consideration in this study since it can resolve the over-learning issue and is effective at detecting noise and outliers. It is also one of the best techniques for identifying the most significant feature among the features of the data set (15-20).

RESULTS

Table 1 contains the confusion matrix for the RF model in the test data set. While the RF model could not distinguish 4 patients with heart disease, it accurately predicted 121 patients.

Table 1. Confusion Matrix for the RF model

Predict	References	
	Control	Heart disease
Control	103	4
Heart disease	9	121

Table 2 shows the performance criteria obtained with the RF model in the test data set. In Figure 1, the learning curve of the model in train, test and resampling is given. Based on the results from the

RF model, balanced accuracy, accuracy, sensitivity, F1-score, negative predictive value, positive predictive value, and specificity for heart disease were 0.945, 0.945, 0.920, 0.941, 0.931, 0.963, and 0.968, respectively.

Table 2. Values for performance metrics for the RF model

Table 2. Values for performance metrics for the RF model

Metric	Value
Balanced Accuracy	0.945
Accuracy	0.945
Sensitivity	0.920
F1-score	0.941
Negative predictive value	0.931
Positive predictive value	0.963
Specificity	0.968




Figure 1. The learning curve for model accuracy performance

In Figure 2, the order of importance and the importance coefficients of the variables included in the model are given according to the contribution of the RF model to the prediction performance. According to the results of the study,

the slope of the peak exercise being the unslowing of the ST segment and the maximum heart rate were the first two features that contributed the most to the estimation performance of the RF model. In addition, the peak exercise ST segment down sloping did not contribute to the determination of heart disease.




Figure 2. The graphic of feature importance for the RF model

DISCUSSION

Heart diseases are one of the leading causes of death in the world. A heart attack is a physiological condition characterized by severe chest pain and the possibility of death as a result of heart failure caused by a problem with the coronary arteries. A heart attack occurs when the heart's oxygen supply is cut off due to a rapid decrease or interruption of blood flow in the vessels that feed the heart. The clogged vessel can damage or even kill the heart muscle. Heart attack is the most common health problem in rich countries. It is an important health problem that has become more common in underdeveloped countries. The World Health Organization estimates that more than 16 million people die each year due to heart attacks. These results are one-third of all deaths (1, 21-23).

The development of health care has enabled studies such as identifying the variables

underlying heart diseases and avoiding its occurrence. Recent studies have been able to pinpoint heart disease risk factors, but many scientists agree that further studies are necessary before we can apply this knowledge to lower the prevalence of heart disease. Different factors may contribute to heart problems. Reducing these heart disease risk factors may really help prevent heart disease, according to certain research studies. The prevention of heart disease risk has been the subject of numerous studies. There will be more options to avoid heart disease as more studies on the condition are conducted (24, 25).

For this reason, early detection and treatment of heart diseases are very important. The use of data mining methods for heart diseases is an important research topic. Based on this, we predicted heart disease with a fast and high-performance model using the heart disease dataset containing clinical data in this study.

The performance criteria obtained from the RF method in the study; balanced accuracy, accuracy, sensitivity, F1-score, negative predictive value, positive predictive value, and specificity for heart disease were 0.945, 0.945, 0.920, 0.941, 0.931, 0.963, and 0.968, respectively.

CONCLUSION

In conclusion, this study can suggest an RF algorithm for the development of predictive models for heart diseases and the developed model can help clinicians in the early diagnosis of cardiac patients.

Ethics Committee Approval: Ethics committee approval is not required in this study.

Peer-review: Externally peer-reviewed.

Author Contributions:

Concept: Design: Literature search: Data Collection and Processing: Analysis or Interpretation: Written by: BY

Conflict of Interest: The author declared no conflict of interest

Financial Disclosure: The author declared that this study has not received no financial support.

REFERENCES

1. Yilmaz R, Yağın FH. Early detection of coronary heart disease based on machine learning methods. *Medical Records*. 2022;4(1):1-6.
2. Absar N, Das EK, Shoma SN, Khandaker MU, Miraz MH, Faruque M, et al., editors. The Efficacy of Machine-Learning-Supported Smart System for Heart Disease Prediction. *Healthcare*; 2022: MDPI.
3. Demir De. Classification Of Heart Attack Risks with Artificial Intelligence Methods. *Artificial Intelligence Applications and Their Economic Effects on The Field Of Health Care*. 2022:9.
4. Yilmaz R, Yağın FH. A comparative study for the prediction of heart attack risk and associated factors using MLP and RBF neural networks. *The Journal of Cognitive Systems*. 2021;6(2):51-4.
5. Paksoy N, Yağın FH. Artificial Intelligence-based Colon Cancer Prediction by Identifying Genomic Biomarkers. *Medical Records*.4(2):196-202.
6. Akbulut S, Yagin FH, Colak C. Prediction of COVID-19 Based on Genomic Biomarkers of Metagenomic Next. *Biomed Eng*. 2020;14:4-15.
7. Hamet P, Tremblay J. Artificial intelligence in medicine. *Metabolism*. 2017;69:S36-S40.
8. Haick H, Tang N. Artificial intelligence in medical sensors for clinical decisions. *ACS nano*. 2021;15(3):3557-67.
9. Koteluk O, Wartecki A, Mazurek S, Kołodziejczak I, Mackiewicz A. How do machines learn? artificial intelligence as a new era in medicine. *Journal of Personalized Medicine*. 2021;11(1):32.
10. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial intelligence in cancer research and precision medicine. *Cancer Discovery*. 2021;11(4):900-15.
11. Yağın FH, Yağın B, Arslan AK, Çolak C. Comparison of Performances of Associative Classification Methods for Cervical Cancer Prediction: Observational Study. *Turkiye Klinikleri Journal of Biostatistics*. 2021;13(3).
12. Akbulut S, Yagin FH, Colak C. Prediction of Breast Cancer Distant Metastasis by Artificial Intelligence Methods from an Epidemiological Perspective. *Istanbul Medical Journal*. 2022;23(3).

13. Han J, Pei J, Tong H. Data mining: concepts and techniques: Morgan kaufmann; 2022.
14. Siddhartha M. Heart disease dataset (comprehensive). IEEE Dataport. 2020.
15. Perçin İ, Yağın FH, Arslan AK, Çolak C, editors. An interactive web tool for classification problems based on machine learning algorithms using java programming language: data classification software. 2019 3rd International Symposium on Multidisciplinary Studies and Innovative Technologies (ISMSIT); 2019: IEEE.
16. Cicek İB, İlhami S, Yağın FH, Colak C. Development of a Python-Based Classification Web Interface for Independent Datasets. Balkan Journal of Electrical and Computer Engineering.10(1):91-6.
17. Oshiro TM, Perez PS, Baranauskas JA, editors. How many trees in a random forest? International workshop on machine learning and data mining in pattern recognition; 2012: Springer.
18. Khan MA, Memon SA, Farooq F, Javed MF, Aslam F, Alyousef R. Compressive strength of fly-ash-based geopolymer concrete by gene expression programming and random forest. Advances in Civil Engineering. 2021;2021.
19. Gupta VK, Gupta A, Kumar D, Sardana A. Prediction of COVID-19 confirmed, death, and cured cases in India using random forest model. Big Data Mining and Analytics. 2021;4(2):116-23.
20. Mohana RM, Reddy CKK, Anisha P, Murthy BR. Random forest algorithms for the classification of tree-based ensemble. Materials Today: Proceedings. 2021.
21. Bhuyan SK, Sahoo H, Habada SK, chandra Pradhan P. Prevalence of Coronary Heart Disease (CHD) risk factors-a hospital based cross sectional survey from South Odisha.
22. Aravinda C, Lin M, Kumar U, Reddy K, Prabhu GA. Deep Learning Techniques for Data Analysis Prediction in the Prevention of Heart Attacks. Internet of Healthcare Things: Machine Learning for Security and Privacy. 2022:217-40.
23. Kavitha M, Gnaneswar G, Dinesh R, Sai YR, Suraj RS, editors. Heart disease prediction using hybrid machine learning model. 2021 6th International Conference on Inventive Computation Technologies (ICICT); 2021: IEEE.
24. Humphries SE, Drenos F, Ken-Dror G, Talmud PJ. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121(20):2235-48.
25. Kim J, Lee J, Lee Y. Data-mining-based coronary heart disease risk prediction model using fuzzy logic and decision tree. Healthcare informatics research. 2015;21(3):167-74.

CASE REPORT/OLGU SUNUMU

Hydatid Cyst Mimickers and Cases Mimicked by Hydatid Cyst; With Two Cases

Havva Erdem¹(ID), Ülkü Karaman²(ID)

¹Department of Pathology, Faculty of Medicine, Ordu University, Ordu, Turkey

²Department of Parasitology, Faculty of Medicine, Ordu University, Ordu, Turkey

Received: 07 October 2022, Accepted: 30 November 2022, Published online: 31 December 2022

© Ordu University Institute of Health Sciences, Turkey, 2022

Abstract

Hydatid cyst is a parasitic disease caused by *Echinococcus granulosus* and is frequently seen in Turkey. Cystic lesions are frequently encountered in routine examinations. These lesions include a wide spectrum from benign to malignant.

Imaging methods are frequently used in the diagnosis, and many cystic hepatic and extrahepatic lesions have different imaging findings. In addition, in some cases, radiological evaluation is not sufficient for a definitive diagnosis. In this case, the diagnosis can be made by evaluating the sample taken from the pathological point of view. Some lesions may also mimic diseases such as hydatid cysts.

In this study, two hepatic cyst cases, which are thought to cause difficulties in diagnosis and may adversely affect the treatment process, are presented because the cyst imitates hydatid disease.

In conclusion, hydatid cysts and hydatid mimics should be kept in mind especially in endemic regions, hepatic and extrahepatic regions.

Key Words: Hydatid cyst, mimics, liver, extrahepatic

Hidatik Kist Taklitçileri ve Hidatik Kisti Taklit Eden Olgular; İki Olgu

Özet

Kist hidatik *Echinococcus granulosus*'un neden olduğu paraziter bir hastalık olup Türkiye'de sıklıkla görülmektedir. Rutin incelemelerde kistik lezyonlar ile sıklıkla karşılaşılmaktadır. Bu lezyonlar benignitten maligniteye kadar geniş bir yelpazeyi içermektedir.

Tanıda sıklıkla kullanılan görüntüleme yöntemleri olup birçok kistik hepatic ve ekstrahepatic lezyonun farklı görüntüleme bulguları vardır. Ayrıca bazı durumlarda kesin tanı için radyolojik değerlendirme de yeterli olmamaktadır. Bu durumda alınan örneğin patolojik açıdan değerlendirilerek tanısı konulabilmektedir. Bazı lezyonlar da kist hidatik gibi hastalıkları taklit edebilir.

Çalışmada Kist hidatigi taklit etmesi nedeniyle tanıda zorlulara neden olan ve bu doğrultuda tedavi sürecini olumsuz etkileyebileceği düşünülen iki hepatic kist olgusu sunuldu.

Sonuç olarak, özellikle endemik bölgelerde, hepatic ve ekstrahepatic bölgelerde hidatik kistler ve hidatik taklitçileri akılda tutulmalıdır.

Anahtar Kelimeler: kist hidatik, mimik, karaciğer, ekstrahepatic

Suggested Citation: Erdem H, Karaman U. Hydatid cyst mimickers and cases mimicked by hydatid cyst; with two cases. ODU Med J, 2022;9(3): 110-115.

Copyright@Author(s) - Available online at <https://dergipark.org.tr/tr/pub/odutip>

Content of this journal is licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Address for correspondence/reprints:

Havva Erdem

Telephone number: +90 (452) 226 52 14

E-mail: havvaerdem @odu.edu.tr

NOTE: This article was presented as an oral presentation at the 9th National Hydatidology and 2nd International Hydatidology congress.

INTRODUCTION

Hydatid cyst is a parasitic infection usually caused by *Echinococcus granulosus*. The main source of this parasite is carnivores. These are mostly dogs, wolves, foxes. People get these eggs from raw fruits and vegetables that are not well washed and cooked. Contamination is possible from contaminated drinking water. In addition to humans, ruminant animals such as sheep, goats, cattle and buffalo also get sick by ingesting the eggs (1).

Hydatid Cysts are mostly localized in the liver (70%) and lung (25%) (2). Primary isolated extrahepatic hydatid cyst is most common in the abdomen, with a rate of 6-11% (2). Although some patients may be asymptomatic, the clinical presentation is mostly abdominal pain or symptoms that may vary according to the localization of the cyst. Swelling in soft tissue, spleen, pancreas, kidney, retroperitoneum, bladder, ovaries, bone, heart, chest wall, spine, thyroid gland, brain and muscles can give symptoms according to their location. They may not show symptoms at first (2).

These cases can mimic many benign or malignant cystic and solid lesions, depending on their location. Many lesions also mimic hydatid cyst and give clinical presentation. In this article, it is aimed to examine the lesions that mimic hydatid cyst and cases mimicked by cyst hydatid through two cases.

CASE REPORTS

Two cases are presented. Necessary information has been provided for the cases.

Case-1: A 71-year-old male patient was brought to the general surgery emergency department with acute abdomen after a traffic accident. During the examination a cystic mass in the liver was detected incidentally. After the patient was stabilized, surgical treatment was applied to this cystic mass and the removed material was sent to pathology for diagnosis. In the examinations, a large number of small and medium-sized vascular structures and hyalinized stroma, filled with erythrocytes, were observed in a focal area, adjacent to the normal liver tissue, in the observed areas. In the immunohistochemical study, a diffuse and strong reaction with CD31 and CD34 was observed in these areas. For differential diagnosis, HepPar1, Alpha fetoprotein (AFP), desmin, monoclonal carcinoembryonic antigen (mCEA) were added to the panel. Nuclear staining (in the most intense area) was observed at a rate of 1-2% with Ki-67. The case was reported as epithelioid hemangioendothelioma (Figures -1,2).




Figure 1: The area where vascular structures are observed in the vicinity of the liver tissue (H&EX200)




Figure 2: Positive staining with CD31 was observed in vascular structures (CD31X200)

Case-2: A 69-year-old female patient was resected with a preliminary diagnosis of hydatid cyst, simple cyst, upon detection of a cystic lesion in the liver. The material was sent to pathology. No cuticle or membranous structure was found in the examinations. Necrosis was not present. In the microscopic examination, there was proliferation and cystic enlargement in the biliary glands. As a result of microscopic

examination, it was found to be compatible with peribiliary cyst (Figure -3).




Figure 3: Biliary glands with cystic dilated appearance (H&EX200), positive staining with CK7 showed ((top left image) (CK7X100)

DISCUSSION

Many cystic lesions have classical imaging findings, and these findings may be sufficient for diagnosis. However, in many cases, there may be similar appearances and therefore histopathological evaluation may be required for a definitive diagnosis.

In the literature, these lesions in liver and non-hepatic localizations have led to difficulties in diagnosis because specific clinical symptoms and laboratory findings are absent in hydatid cysts (3-16).

Cystic liver lesions can be divided into developmental, inflammatory, neoplastic, and trauma-related lesions. Simple liver cysts are the most common lesions encountered incidentally.

The number and morphology of the lesions and the determination of solid components within the lesion are important in the differential diagnosis (3).

Cystic lesions of the liver occur in many cases. Congenital simple cysts occur in polycystic disease, portal fibrosis and Caroli's disease. They are mostly asymptomatic. Cases of hydatid cysts are the most common cause of parasitic disease in the liver. Hemangioendotheliomas, mesenchymal hamartomas, and teratomas are among the cystic neoplasms of the liver (4).

In our first case, radiologically cystic appearance of the hemangioendothelioma caused hydatid cyst to be considered in the diagnosis. A definitive diagnosis was made as a result of histopathological evaluation.

In the study of Gupta et al., they evaluated hepatobiliary cystic lesions and included 72 common choledochal cysts, 51 hydatid cysts, 8 simple liver cysts, 2 changes due to congestive heart failure, 6 biliary cystadenoma, 5 liver abscess and presented the histopathology evaluation of 4 cases of cavernous hemangioma (3). In this evaluation, besides hematoxylin-eosin preparations, histochemical stainings such as silver reticulin, Masson's trichrome, periodic acid Schiff (PAS), Voehrhoff Van Gieson were also used. These histochemical stains will not be discussed in this article.

In the second case we presented, if we examine the subject through peribiliary cysts,

these lesions are formed by the localization of the intrahepatic, extramural peribiliary glands at the hepatic hilum and portal tract levels and showing multiple small dilatations. Peribiliary cysts are multiple and may be discrete, clustered, or confluent. It can mimic compound type biliary ductal dilatation (5).

There are many lesions that mimic hydatid cysts. Examples of these lesions are bronchogenic cysts, gossypiboma, schwannoma located in the lung, mesenchymal hamartoma of the liver. These cases were diagnosed by histopathological evaluation (6-9).

Situations mimicked by hydatid cyst are also among the common problems. Liver and lung hydatid cyst cases can also mimic other diseases (10,11). In one study, a case evaluated as pleural abscess or empyema was treated with broad-spectrum antibiotics and surgical intervention. A hydatid cyst was observed after surgery (10,11). It has been reported that approximately 15-40% of patients with pulmonary hydatid cysts also have cysts in the liver simultaneously (11).

In the case presented by Işık et al., a case of hydatid cyst confused with necrotizing pneumonia is presented. In the case, there was no response to the treatment in the patient who was followed up with the complaint of rash, for whom broad-spectrum antibiotic therapy was started because the radiological findings were consistent with necrotizing pneumonia. Multiple thick-walled cystic lesions and pleural effusions were

observed in the computerized tomography, and it was stated that the diagnosis of pulmonary hydatid cyst disease was confirmed by surgical and serological examinations (11).

It has been reported that hydatid cysts located in the heart and deep muscle, as well as in the lung, can cause serious confusion and the diagnosis is clarified by histopathological evaluation after resection. Especially muscle localized mass lesions can mimic soft tissue tumors. Especially in endemic areas, careful evaluation is beneficial. Sometimes there may be a solid appearance without a cystic component (12,13).

Although single, cardiac localized mass lesions have more specific images radiologically, the diagnosis was made after resection in the case presented by Parsaee et al. (12).

Although muscular hydatid cysts are rarely seen, they should be kept in mind in the differential diagnosis in surgical planning because of the risk of anaphylactic reaction as well as recurrence in incomplete surgery (13).

In the literature, cases of phantom tumor, kidney tumor and lung cancer, which have difficulties in differential diagnosis with hydatid cyst, have also been reported (14-16).

CONCLUSIONS

In conclusion, hydatid cysts should be considered in the differential diagnosis of cystic or solid lesions, especially in endemic areas. In the definitive diagnosis, clinical as well as

radiological and pathological evaluation results should be evaluated together.

Ethics Committee Approval: Not required

Peer-review: Externally peer-reviewed.

Author Contributions:

Concept: HE, UK.; Design: HE, UK.; Literature search: HE, UK; Data Collection and Processing HE, UK.; Analysis or Interpretation: HE, UK.; Writing: HE, UK.

Conflict of Interest: The authors declared no conflict of interest

Financial Disclosure: The authors declared that this study has not received no financial support.

References

1. T.C. Ministry of Health. Hydatid cyst (Kistik Ekinokokkoz). 2015. <https://www.saglik.gov.tr/TR,4076/kistik-hidatik-kistik-ekinokokkoz.html> date of access (3.10.2022).
2. Aksakal N, Kement M, Okkabaz N, Altuntaş YE, Öncel M. Unusually located primary hydatid cysts. *Ulus Journal of Surgery*. 2015;32(2):130-3.
3. Gupta SM. Histopathological assessment hepatobiliary cystic lesions in tertiary care centre. *J Adv Med Dent Scie Res* 2019;7(9):214-217.
4. Ramachandran, P. Hepatic Cysts and Abscesses. In: Puri, P, Höllwarth M. (eds) *Pediatric Surgery*. Springer, Berlin:

- Heidelberg; 2009. p.557-558.
5. Borhani AA, Wiant A, Heller MT. Cystic hepatic lesions: a review and an algorithmic approach. *AJR Am J Roentgenol.* 2014; 203(6):1192-204.
 6. Tokur M, Yesilkaya Y, Ozkan F, Tokur N. Bronchogenic cyst mimicking hydatid cyst or infected bulla in child patient. *Eastern Journal of Medicine.* 2013; 18(3): 133-135.
 7. Ozutek A, Karabuga T, Bozdog AD, Hayrullah Derici. Asymptomatic gossypiboma mimicking a liver mass. *Turk J Surg.* 2010;26:225-8.
 8. ErkanAkar. Schwannoma mimicking pulmonary hydatid cyst: Case report. *Respir Case Rep.* 2012; 1(1): 15-18
 9. Ataş E, Demirkaya M, Kesik V, Balamtekin N, Kocaoglu M Mesenchymal Hamartoma of the Liver Mimicking Hydatid Cyst. *Pediatr Therapeut.* 2012; 2:120.
 10. Kayhan S, Akgünes A. Histopathologically diagnosed pulmonary complicated hydatid cyst cases. *Turkish Journal of Parasite.* 2011; 35: 189-93.
 11. Isık S, Çağlayan Sozmen S, Guzeloglu E, Ozturk T, Asilsoy S. Pulmonary hydatid cyst disease mimicking necrotizing pneumonia in a child with leukocytoclastic vasculitis: a case report. *Turk Pediatri Ars* 2018; 53: 117-9.
 12. Parsaee M, Mohebbi B, Shojaeifard M, Noohi F, Mohebbi A, Bassiri H et al. Hydatid Cyst Mimicking Heart Tumor. *Iranian Heart Journal* 12(3):51-56
 13. Basarir K, Saglik Y, Yildiz Y, Yetis T, Cebesoy O. Primary muscular hydatidosis mimicking soft tissue tumour: a report of five cases. *J Orthop Surg (Hong Kong).* 2008;16(3):368-72.
 14. Ozyigit I, Kocyigit B, Altay S. Hydatid cyst in a heart failure patient mimicking phantom tumor. *Turkish Med Stud J* 2021;8(3):125-7.
 15. Camtosun A, Çelik H, Yıldız A, Altıntaş A, Taşdemir C. A Case of Hydatid Cyst Mimicking Kidney Tumor. *Cyprus J Med Sci* 2019; 4(1): 70-2.
 16. Düzgün N, Esmel H, Duran FM, Kurtipek E. Lung Carcinoma Mimicking Hydatid Cyst: A Case Report. *J Clin Anal Med* 2013;4(suppl 5): 512-4

CASE REPORT/OLGU SUNUMU

Barrett's Esophagus; Case Report

Gülden Yıldız¹(ID), Hatice Beşeren Havadar¹(ID), Tülay Diken Allahverdi²(ID)

¹Department of Pathology, Faculty of Medicine, Kafkas University, Kars, Turkey

²Department of General Surgery, Faculty of Medicine, Kafkas University, Kars, Turkey

Received: 08 August 2022, Accepted: 30 October 2022, Published online: 31 December 2022

©Ordu University Institute of Health Sciences, Turkey, 2022

Abstract

Barrett's esophagus is the transformation of the normal squamous epithelium in the distal esophagus into columnar epithelium with intestinal metaplasia. Barrett's esophagus generally develops as a result of chronic mucosal irritation due to gastroesophageal reflux. Although Barrett's esophagus is usually seen over the age of 50, it can also be seen at younger ages. In our case, it was seen in a 34-year-old male patient. The patient applied to the general surgery outpatient clinic with complaints of swelling in the stomach, pain and watering in the mouth. When endoscopy is performed; the cervical and thoracic esophageal mucosa appeared normal, and the Z line was 40 cm distally. The esophageal mucosa had a hyperemic appearance. Multiple biopsies were taken from these areas. In histopathological evaluation, special columnar epithelium, mucin-filled cytoplasm, goblet cells (intestinal metaplasia) were observed. Goblet cells were positively stained by PAS/Alcian Blue and Mucincarmine histochemical staining.

Key Words: Barrett's esophagus, gastroesophageal reflux, intestinal metaplasia

Barrett Özofagus; Olgu Sunumu

Özet

Barrett özofagus, distal özofagustaki normal skuamöz epitelin intestinal metaplazi ile kolumnar epitele dönüşmesidir. Barrett özofagus genellikle gastroözofagial reflüye bağlı kronik mukozal irritasyon sonucu gelişmektedir. Barrett's özofagusu genellikle 50 yaş üzerinde görülmekle birlikte daha genç yaşlarda da görülebilmektedir. Bizim olgumuzda 34 yaşında erkek hastada görülmüştür. Hasta midede şişlik, ağrı ve ağızda sulanma şikayetleri ile genel cerrahi polikliniğine başvurmuştur. Endoskopi yapıldığında; servikal ve torasik özofagus mukozası normal görünümdeydi, Z çizgisi distalde 40 cm idi. Özofagus mukozası hiperemik bir görünüme sahipti. Bu alanlardan birden fazla biyopsi alındı. Histopatolojik değerlendirmede; özel kolumnar epitel, müsin dolu sitoplazma, goblet hücreleri (bağırsak metaplazisi) gözlemlendi. Goblet hücreleri, PAS/Alcian Blue ve Mucincarmine histokimyasal boyama ile pozitif olarak boyandı.

Anahtar Kelimeler: Barrett özofagus, gastroözofagial reflü, intestinal metaplazi

Suggested Citation: Yıldız G, Beşeren H. H, Diken Allahverdi T. Barrett's Esophagus; Case Report. ODU Med J, 2022;9(3): 110-115.

Copyright@Author(s) - Available online at <https://dergipark.org.tr/tr/pub/odutip>

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Address for correspondence/reprints:

Hatice Beşeren

Telephone number: +90 (555) 174 33 83

E-mail: haticebeseren@hotmail.com

INTRODUCTION

Barrett's esophagus is defined as the replacement of normal squamous epithelium in the distal part of the esophagus with columnar epithelium containing intestinal metaplasia (1). In fact, although Tileston was the first to describe the columnar epithelial line in the lower esophagus, the lesion was first described by Norman Barrett in 1950 as a congenitally short esophagus accompanied by an intrathoracic stomach, and it was later reported that the lesion had abnormal columnar epithelial alignment in the distal esophagus (2). Barrett later explained that the disease is acquired (3). Today, for the definition of Barrett's esophagus, it is necessary to both endoscopically visualize the columnar line in the esophagus and detect the presence of intestinal metaplasia by biopsy (3). In the case report, we aimed to present a case diagnosed as Barrett's esophagus on tissue taken by endoscopic biopsy to emphasize the importance of Barrett's esophagus.

CASE REPORTS

In our case, it was seen in a 34-year-old male patient. The patient applied to the general surgery outpatient clinic with complaints of swelling in the stomach, pain and watering in the mouth. When endoscopy is performed; the cervical and thoracic esophageal mucosa appeared normal, and the Z line was 40 cm distally. The esophageal mucosa had a hyperemic appearance. Multiple biopsies were taken from these areas. In

histopathological evaluation, special columnar epithelium, mucin-filled cytoplasm, goblet cells (intestinal metaplasia) were observed. Goblet cells were positively stained by PAS/Alcian Blue and Mucincarmine histochemical staining.

DISCUSSION

Barrett's esophagus patients typically present with symptoms of gastroesophageal reflux disease (GERD) (5). Heartburn and regurgitation are major symptoms (4). There may also be dysphagia, odynophagia, chest pain. While some patients have symptoms at first, they may disappear later, because the areas of esophagitis transform into columnar epithelium, which is less sensitive to acid (5). Most of the patients are middle-aged, smokers and alcohol users. Barrett's esophagus patients may also be symptom-free. The frequency and duration of heartburn are associated with increased frequency of Barrett's esophagus, but the severity of reflux symptoms is inversely proportional to Barrett's esophagus (6). Among the symptoms of Barrett's esophagus, extraesophageal findings such as hematemesis, melena, occult gastrointestinal bleeding and hoarseness, asthma and dental disorders can be seen (5,6). Erosion and ulceration, peptic ulcer, fistula formation, stricture, dysplasia, and tumor development are the main complications and symptoms related to these complications may also develop (7). Dysphagia is an important finding that may suggest adenocarcinoma. Similarly,

gastrointestinal bleeding may be related to esophageal ulcer and severe esophagitis (8). If the cause of chronic blood loss cannot be explained by colonoscopy, such patients should undergo Barrett's esophagus and upper gastrointestinal system endoscopy for esophagitis (9).

Esophageal adenocarcinoma (EAC) is a very deadly type of cancer, and it is the fastest growing cancer type with an annual increase rate of 4-10% in the Americas and Europe (8,9). Barrett's esophagus is the only known precursor lesion of EAC and usually occurs due to GERD (14). However, adenocarcinoma develops in only 1.3-5% of patients with Barrett's esophagus, and the time required for this is estimated to be 20-30 years (10). The risk of developing EAC in patients with Barrett's esophagus is 30-125 times higher than in normal people (11). The aim of Barrett's esophageal screening in patients with gastroesophageal reflux disease is to detect esophageal cancer in an early and treatable period and to reduce EAC-related deaths (11,12). The American Gastroenterology Association reported that upper gastrointestinal system (GIS) endoscopy should be performed in patients with chronic GERD because of the high incidence of Barrett esophagus, but whether routine screening is necessary or not is still controversial (13). The median age at diagnosis of Barrett's esophagus was 40, and the age of development of EAC was 64. Eloubeidi and Provenzale stated that over the

age of 40 is an independent predictor for Barrett's esophagus (14). Therefore, it is considered appropriate to start Barrett's esophageal screening at this age. Although there is no definitive evidence, it is thought that Barrett's esophageal screening is cost-effective and reduces mortality due to EAC (13,14).

Goblet cells do not show regular distribution in Barrett's esophagus, and their rates differ significantly between patients and specimens (15). Columnar cells among goblet cells resemble gastric foveolar cells or intestinal absorptive cells. Pseudogoblet cells, similar to goblet cells but containing neutral mucin, may be misleading in diagnosis. In Barrett's esophagus, the predominant form of intestinal metaplasia-incomplete intestinal metaplasia consists of a mixture of goblet cells and foveolar type epithelium containing PAS-positive neutral mucin (14,15). These foveolar epithelial cells may contain Alcian Blue-positive acidic mucin, which shows less intense staining than that observed in goblet cells, but detection of Alcian Blue-positive columnar cells is not sufficient for the definitive diagnosis of Barrett's esophagus in the absence of goblet cells (16). Less frequently, the glandular component contains varying proportions of goblet cells, well-formed intestinal absorptive cells. In some cases, incomplete and complete intestinal metaplasia coexist. Pancreatic acinar metaplasia can also be detected, but its diagnostic significance is limited

(17). Typically, the lamina propria shows mild chronic inflammation and fibrosis, with marked thickening and separation, or double-ordering, of the muscularis mucosa. Intestinal metaplasia is mixed with cardiac-type or fundic-type epithelial foci corresponding to normal gastric mucosa, except for varying degrees of mucosal distortion, glandular atrophy, and mild inflammation (18). In the biopsy specimen taken from the distal esophagus in Barrett's esophagus, cardiac or fundic type mucosa without intestinal metaplasia (at least 2 cm columnar esophagus) and absence of goblet cells may be the result of sampling error only (17,18).

The treatment approach in Barrett's esophagus should aim to:

- (i) relieve reflux symptoms.
- (ii) prevent reflux of acid and duodenal contents into the esophagus.
- (iii) prevent complications such as erosion, peptic ulcer and stricture.
- (iv) arresting the proximal progression of intestinal metaplasia.
- (v) accelerate regression of intestinal metaplasia to normal mucosa.
- (vi) halt the progression to dysplasia.
- (vii) accelerate regression of dysplasia to nondysplastic cells.
- (viii) stop the progression to adenocarcinoma (19).

The treatment of Barrett's esophagus determines whether high-grade dysplasia (HDD)

is present. In Barrett's esophagus without high-grade dysplasia, the most preferred option is medical therapy (20). Developing medical drugs are sufficient to prevent symptoms in most of the patients. Medical treatment can be successful not only in preventing typical reflux symptoms but also in treating cases with complications (19,20). It has been reported that proton pump inhibitors (PPI) are more effective in relieving reflux symptoms compared to H2 receptor blockers. With proton inhibitor therapy, improvement and improvement in symptoms was detected in 95% of patients with erosive esophagitis and Barrett's ulcer (21). Proton inhibitor also reduce bile reflux by reducing gastric secretions. It is difficult to determine the duration of medical therapy in patients with Barrett's esophagus, as discontinuation of treatment almost always causes exacerbation of reflux symptoms (22). Despite symptomatic improvement with medical treatment, complete regression of Barrett's epithelium is not achieved with neither PPI nor H2 receptor blockers. Although aggressive antireflux therapies are successful in reflux control, they cause achlorhydria and increase the risk of adenocarcinoma development

CONCLUSIONS

Ochronosis is a disease that shows autosomal Barrett's esophagus is usually seen over the age of 50, but it can also be seen at younger ages. Follow-up should be done more frequently in younger patients. The risk of developing cancer

in the Barrett esophagus floor is high. The risk of developing cancer in the Barrett esophagus floor is high. The presence and degree of dysplasia in Barrett's esophagus determines the type of treatment to be applied. In cases with non-dysplasia and low-grade dysplasia, medical treatment, antireflux surgery or ablation methods should be preferred.

Ethics Committee Approval: Consent form was filled out by all participants.

Peer-review: Externally peer-reviewed.

Author Contributions:

Concept: TDA, HBH, Design: TDA, HBH; Literature search: GY; Data Collection and Processing TDA, HBH; Analysis or Interpretation: GY, TDA; Writing: TDA, HBH.

Conflict of Interest: The authors declared no conflict of interest

Financial Disclosure: The authors declared that this study has not received no financial support.

REFERENCES

1. De Palma GD. Management strategies of Barrett esophagus, *World J Gastroenterol* 2012; 18:6216-25.
2. Schouten LJ, Steevens J, Huysentruyt CJ, et al. Total cancer incidence and overall mortality are not increased among patients with Barret's esophagus. *Clin Gastroenterol Hepatol* 2011;9:754-61.
3. Spechler SJ. Barret' esophagus: Clinical issues Barrett's esophagus: Clinical issues. *Gastrointest Endosc Clin N Am* 2011;21:1-7.
4. Bhardwaj A, McGarrity TJ, Stairs DB, Mani H. Barrett's esophagus: Emerging knowledge and management strategies. *Patholog Res Int* 2012; 2012: 814146.
5. Vahabzadeh B, Seetharam AB, Cook MB, et al. Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. *Gastrointest Endosc* 2012;75:236-41.
6. Leggett CL, Nelsen EM, Tian J, et al. Metabolic syndrome as a risk factor for barrett esophagus: a population-based case-control study. *Mayo Clin Proc* 2013;88:157-65.
7. El-Serag HB, Hashmi A, Garcia J, et al. Visceral Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett's oesophagus: a case-control study. *Gut* 2013 Feb 13 (Epub).
8. Thompson OM, Beresford SA, et al. Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction. *Obesity (Silver Spring)* 2010;18:2204-11.
9. Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. *Clin Gastroenterol Hepatol*. 2013 Mar 1. pii: S1542- 3565(13)00274-7.
10. Tytgat GN. Recent developments in

- gastro-esophageal reflux disease and Barrett's esophagus: *J Dig Dis* 2012;13:291-5.
11. Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. *Gastroenterology* 2011;141:1179-86.
 12. Wani S. Management of low-grade dysplasia in Barrett's esophagus. *Curr Opin Gastroenterol* 2012;28:370-6.
 13. Moyes LH, Going JJ. Still waiting for predictive biomarkers in Barrett's oesophagus. *J Clin Pathol* 2011;64:742-50.
 14. Verbeek RE, van Oijen MG, ten Kate FJ, et al. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study. *Am J Gastroenterol* 2012;107: 534-42.
 15. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. *Gastroenterology* 2011;141:460-8.
 16. Zhang ZF, Kurtz RC, Sun M, Karpeh M Jr, Yu GP, Gargon N, et al. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. *Cancer Epidemiol Biomarkers Prev* 1996;5:761-8.
 17. Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2001;10:1055-62.
 18. Sartori S, Nielsen I, Indelli M, Trevisani L, Pazzi P, Grandi E. Barrett esophagus after chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF): an iatrogenic injury? *Ann Intern Med* 1991;114:210-1.
 19. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J, et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. *Gut* 2002;51:323-8.
 20. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut* 2006;55:1810-20.
 21. Schier S, Wright NA. Stem cell relationships and the origin of gastrointestinal cancer. *Oncology* 2005;69 Suppl 1:9-13.
 22. Yu WY, Slack JM, Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. *Dev Biol* 2005;284:157-70.
 23. Seery JP. Stem cells of the oesophageal epithelium. *J Cell Sci* 2002;115:1783-9.